var docs;if (!docs) docs =[]; docs["76"]={"7604":"<p><b>Title</b> Beta2-Agonists (Long-Acting) / Beta2-Agonists (Long-Acting)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Beta2-Agonists (Long-Acting) may enhance the adverse/toxic effect of other Beta2-Agonists (Long-Acting). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of one long-acting beta2-agonist with another long-acting beta2-agonist should be avoided due to the risk for toxicity.</p>\n<div>\n <p><b>Beta2-Agonists (Long-Acting) Interacting Members</b> Arformoterol, Bambuterol, Formoterol, Indacaterol, Olodaterol, Salmeterol, Tulobuterol, Vilanterol</p>\n</div> \n<p><b>Discussion</b> The prescribing information for all medications that contain a long-acting beta2-agonist advise against the concurrent use of other long-acting beta2-agonists due to the potential for overdose, which has been associated with significant cardiovascular effects and fatalities.<sup>1,2,3,4,5,6,7,8</sup> According to one case report, a patient experienced sinus tachycardia, ST segment depression, hypokalemia, hypophosphatemia, and lactic acidosis associated with a fluticasone/salmeterol overdose.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Serevent Diskus (salmeterol). Research Triangle Park, NC: GlaxoSmithKline, December 2010.</p>\n<p>2. Prescribing information. Advair Diskus (fluticasone propionate/salmeterol). Research Triangle Park, NC: GlaxoSmithKline, January 2011.</p>\n<p>3. Prescribing information. Foradil Aerolizer (formoterol). Whitehouse Station, NJ: Merck &amp; Co., Inc., November 2012.</p>\n<p>4. Prescribing information. Symbicort (budesonide/formoterol). Wilmington, DE: AstraZeneca LP., June 2010.</p>\n<p>5. Prescribing information. Dulera (formoterol/mometasone). Whitehouse Station, NJ: Merck &amp; Co., Inc., 2010.</p>\n<p>6. Prescribing information. Breo Ellipta (fluticasone furoate/vilanterol). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p>7. Prescribing information. Brovana (arformoterol). Marlborough, MA: Sunovion Pharmaceuticals Inc., February 2012.</p>\n<p>8. Prescribing information. Arcapta Neohaler (indacaterol). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2012.</p>\n<p>9. Manara A, Hantson P, Vanpee D, et al, “Lactic Acidosis following Intentional Overdose by Inhalation of Salmeterol and Fluticasone.” <i>CJEM</i>, 2012, 14(6):378-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23131487\">[PubMed 23131487]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7606":"<p><b>Title</b> Tegafur / CYP2A6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2A6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tegafur. Specifically, CYP2A6 inhibitors may inhibit the conversion of tegafur into its active metabolite, 5-fluorouracil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of tegafur with a CYP2A6 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP2A6 Inhibitors (Strong) Interacting Members</b> Letrozole, Methoxsalen (Systemic), Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Tegafur is converted into its active metabolite, 5-fluorouracil, via CYP2A6 metabolism.<sup>1</sup> Consequently, coadministration with a CYP2A6 inhibitor should be avoided since such a combination could impair the clinical effectiveness of tegafur.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7607":"<p><b>Title</b> Tegafur / CYP2A6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2A6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tegafur. Specifically, CYP2A6 inhibitors may inhibit the conversion of tegafur into its active metabolite, 5-fluorouracil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of tegafur with a CYP2A6 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP2A6 Inhibitors (Moderate) Interacting Members</b> Amiodarone, Desipramine, Isoniazid, Ketoconazole (Systemic)</p>\n</div> \n<p><b>Discussion</b> Tegafur is converted into its active metabolite, 5-fluorouracil, via CYP2A6 metabolism.<sup>1</sup> Consequently, coadministration with a CYP2A6 inhibitor should be avoided since such a combination could impair the clinical effectiveness of tegafur.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7608":"<p><b>Title</b> Fluorouracil (Systemic) / Gimeracil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gimeracil may increase the serum concentration of Fluorouracil (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine (such as fluorouracil) is contraindicated.</p> \n<p><b>Discussion</b> Due to gimeracil's actions as an inhibitor of dihydropyrimidine dehydrogenase (DPD), which is the enzyme primarily responsible for metabolism of fluorouracil, concurrent use of gimeracil with fluoropyrimidines is likely to increase fluorouracil concentrations and effects. Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7609":"<p><b>Title</b> Capecitabine / Gimeracil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gimeracil may increase serum concentrations of the active metabolite(s) of Capecitabine. Specifically, gimeracil may increase concentrations of fluorouracil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine (such as capecitabine) is contraindicated.</p> \n<p><b>Discussion</b> Due to gimeracil's actions as an inhibitor of dihydropyrimidine dehydrogenase (DPD), which is the enzyme primarily responsible for metabolism of fluorouracil, concurrent use of gimeracil with fluoropyrimidines is likely to increase fluorouracil concentrations and effects. Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine (such as capecitabine) is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7610":"<p><b>Title</b> Flucytosine / Gimeracil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gimeracil may increase serum concentrations of the active metabolite(s) of Flucytosine. Specifically, gimeracil may increase concentrations of fluorouracil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine (such as flucytosine) is contraindicated.</p> \n<p><b>Discussion</b> Due to gimeracil's actions as an inhibitor of dihydropyrimidine dehydrogenase (DPD), which is the enzyme primarily responsible for metabolism of fluorouracil, concurrent use of gimeracil with fluoropyrimidines is likely to increase fluorouracil concentrations and effects. Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine (such as flucytosine) is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7611":"<p><b>Title</b> Tegafur / Gimeracil</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: This contraindication applies specifically to tegafur when used apart from the tegafur-gimeracil-oteracil combination product, and not to the mutual inclusion of these drugs in the combination product.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gimeracil may increase serum concentrations of the active metabolite(s) of Tegafur. Specifically, gimeracil may increase concentrations of fluorouracil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine (including tegafur, when not used as part of this combination product) is contraindicated.</p> \n<p><b>Discussion</b> Due to gimeracil's actions as an inhibitor of dihydropyrimidine dehydrogenase (DPD), which is the enzyme primarily responsible for metabolism of fluorouracil, concurrent use of gimeracil with fluoropyrimidines is likely to increase fluorouracil concentrations and effects. Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine (including tegafur, when not used as part of this combination product) is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7612":"<p><b>Title</b> Floxuridine / Gimeracil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gimeracil may increase serum concentrations of the active metabolite(s) of Floxuridine. Specifically, gimeracil may increase concentrations of fluorouracil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine (such as floxuridine) is contraindicated.</p> \n<p><b>Discussion</b> Due to gimeracil's actions as an inhibitor of dihydropyrimidine dehydrogenase (DPD), which is the enzyme primarily responsible for metabolism of fluorouracil, concurrent use of gimeracil with fluoropyrimidines is likely to increase fluorouracil concentrations and effects. Concurrent use of gimeracil (as a part of the combination product tegafur, gimeracil, and capecitabine) with any other fluoropyrimidine (such as floxuridine) is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7613":"<p><b>Title</b> Vitamin K Antagonists / Tegafur</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tegafur may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor INR and signs/symptoms of bleeding closely when starting or stopping tegafur (alone or as part of a combination product) in a patient receiving a vitamin K antagonist (e.g., warfarin). Anticoagulant dose adjustment will likely be necessary, and effects may increase with subsequent cycles.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The tegafur, gimeracil, and oteracil summary of product characteristics warns that bleeding events and increased INR/PT have been reported in patients using vitamin K antagonists with tegafur, gimeracil, and oteracil in clinical trials.<sup>1</sup><br><br>Similarly, several case reports describe marked increases in PT/INR, accompanied by bleeding, in warfarin-stable patients following the administration of fluorouracil, which is the active metabolite of tegafur (at times in combination with other chemotherapy).<sup>2,3,4,5,6,7,8</sup> One report demonstrated the effects of a regimen containing fluorouracil and levamisole upon both dechallenge and rechallenge of the patient.<sup>7</sup> The lack of reports related to levamisole suggest that the fluorouracil was the causative agent. <br><br>The mechanism of this interaction appears to fluorouracil-mediated inhibition of S-warfarin (most potent enantiomer) metabolism. Though fluorouracil does not appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>9,10</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>9</sup> and losartan/E3174 ratio<sup>11</sup>) following fluorouracil treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>11</sup> An observation that the warfarin dose reductions required during fluorouracil therapy increase with each cycle of fluorouracil further support this time-/dose-dependence.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p>2. Booth BW and Weiss RB, “Venous Thrombosis During Adjuvant Chemotherapy,” <i>N Engl J Med</i>, 1982, 305:170.</p>\n<p>3. Seifter EJ, Brooks BJ, and Urba WJ, “Possible Interactions Between Warfarin and Antineoplastic Drugs,” <i>Cancer Treat Rep</i>, 1985, 69:244-5.</p>\n<p>4. Wajima T and Mukhopadhyay P, “Possible Interaction Between Warfarin and 5-Fluorouracil,” <i>Am J Hematol</i>, 1992, 40:238-43.</p>\n<p>5. Chelobowski RT, Gota CH, Chann KK, et al, “Clinical and Pharmacokinetic Effects on Combined Warfarin and 5-Fluorouracil in Advanced Colon Cancer,” <i>Cancer Res</i>, 1982, 42:4827.</p>\n<p>6. Brown MC, “Multisite Mucous Membrane Bleeding Due to a Possible Interaction Between Warfarin and 5-Fluorouracil,” <i>Pharmacotherapy</i>, 1997, 17:631-3.</p>\n<p>7. Scarfe MA and Israel MK, “Possible Drug Interaction Between Warfarin and Combination of Levamisole and Fluorouracil,” <i>Ann Pharmacother</i>, 1994, 28:464-7.</p>\n<p>8. Kolesar JM, Johnson CL, Freeberg BL, et al, “Warfarin-5-FU Interaction--A Consecutive Case Series,” <i>Pharmacotherapy</i>, 1999, 19(12):1445-9.</p>\n<p>9. Konishi H, Yoshimoto T, Morita K, et al, “Depression of Phenytoin Metabolic Capacity by 5-Fluorouracil and Doxifluridine in Rats,” <i>J Pharm Pharmacol</i>, 2003, 55(1):143-9.</p>\n<p>10. Park JY, Kim KA, “Inhibitory Effect of 5-Fluorouracil on Human Cytochrome P(450) Isoforms in Human Liver Microsomes,” <i>Eur J Clin Pharmacol</i>, 2003, 59(5-6):407-9.</p>\n<p>11. Gunes A, Coskun U, Boruban C, et al, “Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients,” <i>Basic Clin Pharmacol Toxicol</i>, 2006, 98(2):197-200.</p>\n<p>12. Davis DA and Fugate SE, “Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy,” <i>Pharmacotherapy</i>, 2005, 25(3):442-7.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7614":"<p><b>Title</b> Tegafur / Allopurinol</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: The Teysuno branded tegafur product (tegafur, gimeracil, and oteracil) recommends avoiding this combination, while the Uftoral branded product (tegafur and uracil) does not offer any warnings specific to this combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Allopurinol may diminish the therapeutic effect of Tegafur. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent administration of allopurinol with the tegafur, gimeracil, and oteracil (Teysuno brand) combination product should be avoided. The summary of product characteristics for the tegafur and uracil combination product (Uftoral brand) does not contain this warning.</p> \n<p><b>Discussion</b> According to the summary of product characteristics, concurrent administration of the tegafur, gimeracil, and oteracil (Teysuno brand) combination product with allopurinol should be avoided because some data suggest that allopurinol may decrease the intracellular phophorylation of 5-fluorouracil, resulting in diminished effectiveness.<sup>1</sup> In contrast, the summary of product characteristics for the tegafur and uracil combination product (Uftoral brand) does not contain this warning.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p>2. Summary of product characteristics. Uftoral (tegafur and uracil). Feltham, Middlesex, United Kingdom: Merck Serono Ltd, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7615":"<p><b>Title</b> Tegafur / Leucovorin Calcium-Levoleucovorin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Tegafur. This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Enhanced response to fluorouracil, including the potential for greater toxicity, is to be expected with this combination. Since tegafur is a prodrug of fluorouracil, this interaction is likely to apply to tegafur. Monitor closely for fluorouracil toxicities, including diarrhea, mucositis/stomatitis, and neutropenia.</p>\n<div>\n <p><b>Leucovorin Calcium-Levoleucovorin Interacting Members</b> Leucovorin Calcium, LEVOleucovorin</p>\n</div> \n<p><b>Discussion</b> Tegafur is a prodrug of fluorouracil, and the summary of product characteristics for tegafur-containing products caution that folinic acid/folinate may enhance the actions/toxicity of fluorouracil.<sup>1,2</sup> Similarly, the prescribing information for both leucovorin calcium and levoleucovorin caution that these agents can enhance the toxicity of 5-fluorouracil.<sup>3,4</sup> This interaction is used clinically in the treatment of specific cancers in an attempt to enhance the anti-tumor effects of 5-fluorouracil, with studies of different dosing regimens attempting to find ways of maximizing the anti-tumor effects of the combination while minimizing the risk of excessive toxicity.<sup>5,6</sup> Some data suggest that weekly administration of high-dose leucovorin calcium results in less toxicity (primary toxicity with this regimen is diarrhea) than daily (x 5 days) administration of leucovorin calcium, which is associated with multiple toxicities including mucositis, diarrhea, and neutropenia.<sup>5,6</sup><br><br>The mechanism of this interaction involves the conversion of leucovorin calcium or levoleucovorin to the reduced folate 5,10-methylenetetrahydrofolate (CH<sub>2</sub>FH<sub>4</sub>), which then works to stabilize the binding of fluorodeoxyuridine (FdUMP; produced from 5-fluorouracil) to its target, thymidylate synthase.<sup>5,6</sup> FdUMP (i.e., 5-fluorouracil) is more cytotoxic in the presence of CH<sub>2</sub>FH<sub>4</sub> as a result of this enhanced formation/stability of the thymidylate synthase-FdUMP-CH<sub>2</sub>FH<sub>4</sub> complex. Both enhanced anti-tumor effects and greater toxicity of 5-fluorouracil in combination with leucovorin calcium/levoleucovorin result from this same mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p>2. Summary of product characteristics. Uftoral (tegafur and uracil). Feltham, Middlesex, United Kingdom: Merck Serono Ltd, 04/2011.</p>\n<p>3. Prescribing information. Leucovorin calcium. Bedford, OH: Bedford Laboratories, September 2000.</p>\n<p>4. Prescribing information. Levoleucovorin. Irvine, CA: Spectrum Pharmaceuticals, Inc., 2008.</p>\n<p>5. Rustum YM, Cao S, Zhang Z, “Rationale for Treatment Design: Biochemical Modulation of 5-Fluorouracil by Leucovorin,” <i>Cancer J Sci Am</i>, 1998, 4(1):12-8.</p>\n<p>6. Machover D, “A Comprehensive Review of 5-Fluorouracil and Leucovorin in Patients with Metastatic Colorectal Carcinoma,” <i>Cancer</i>, 1997, 80:1179-87.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7616":"<p><b>Title</b> Tegafur / MetroNIDAZOLE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may increase serum concentrations of the active metabolite(s) of Tegafur. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of adverse fluorouracil effects (e.g., hematologic, stomatitis, others) if metronidazole is used concurrently. Tegafur is a prodrug of fluorouracil, so this interaction is similarly possible with tegafur.</p> \n<p><b>Discussion</b> The AUC of fluorouracil was increased by an average of 34% in a study of 27 patients with metastatic colorectal cancer when metronidazole (750 mg/m<sup>2</sup> IV) was given 1 hour prior to fluorouracil (600 mg/m<sup>2</sup> IV) for 5 consecutive days.<sup>1</sup> Several toxic effects of fluorouracil were also noted to be increased with concurrent metronidazole, including granulocytopenia, anemia, thrombocytopenia, stomatitis, and nausea/vomiting.<br><br>A published letter also describes increased fluorouracil-associated neutropenia in a pilot trial in which subjects received concurrent metronidazole as compared to a previous pilot trial in which subjects received an identical fluorouracil regimen but without concurrent metronidazole (4/12 subjects vs. 0/20 subjects with neutropenia, respectively).<sup>2</sup> A study in mice also describes some increase in fluorouracil toxicity with concurrent metronidazole.<sup>3</sup><br><br>The specific mechanism(s) for this interaction is uncertain. Metronidazole treatment was associated with an average 27% reduction in 5-fluorouracil clearance,<sup>1</sup> suggesting that metronidazole may interfere with 5-fluorouracil metabolism and/or elimination, but the precise mechanism(s) by which this occurs is not clear.<br><br>Tegafur is a prodrug of fluorouracil, suggesting this potential interaction may apply to tegafur as well. The summary of product characteristics for a tegafur-containing combination product cautions that use of this combination may result in increased fluorouracil toxicity.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bardakji Z, Jolivet J, Langelier Y, Besner JG, Ayoub J. 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies. <i>Cancer Chemother Pharmacol</i>. 1986;18(2):140-144. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3791559\">[PubMed 3791559]</a></p>\n<p>2. Windle R, Macpherson S, Bell PR. Neutropenia associated with metronidazole. <i>Br Med J</i>. 1979;2(6199):1219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=519366\">[PubMed 519366]</a></p>\n<p>3. Tannock IF. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. <i>Br J Cancer</i>. 1980;42(6):861-870. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7459220\">[PubMed 7459220]</a></p>\n<p>4. Teysuno (tegafur, gimeracil, and oteracil) [summary of product characteristics]. Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7617":"<p><b>Title</b> Tegafur / Methotrexate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methotrexate may enhance the adverse/toxic effect of Tegafur. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution with concurrent use of methotrexate and tegafur, and monitor patients extra closely for evidence of toxicity if the combination is used. Though the tegafur, gimeracil, and oteracil (Teysuno brand) combination product warns about this possible interaction, the summary of product characteristics for the tegafur and uracil combination product (Uftoral brand) does not contain this warning.</p> \n<p><b>Discussion</b> According to the summary of product characteristics, concurrent administration of the tegafur, gimeracil, and oteracil (Teysuno brand) combination product with methotrexate may result in greater fluorouracil (active metabolite of tegafur) effects/toxicity.<sup>1</sup> Like fluorouracil, which inhibits thymidylate synthase, one of methotrexate's actions is also inhibition of thymidylate synthase. As a result caution is recommended when considering use of the combination. In contrast, the summary of product characteristics for the tegafur and uracil combination product (Uftoral brand) does not contain this specific warning.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Teysuno (tegafur, gimeracil, and oteracil). Hoofddoorp, The Netherlands: Nordic Group BV, 11/2012.</p>\n<p>2. Summary of product characteristics. Uftoral (tegafur and uracil). Feltham, Middlesex, United Kingdom: Merck Serono Ltd, 04/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7618":"<p><b>Title</b> Fosphenytoin-Phenytoin / Tegafur</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tegafur may increase the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Phenytoin dose reductions may be necessary when used together with fluorouracil, which is the active metabolite of tegafur. Monitor phenytoin concentrations and response to therapy (both effectiveness and signs/symptoms of toxicity) closely when using this combination.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Several case reports have described phenytoin toxicity associated with concurrent use of fluorouracil<sup>1,2,3</sup> and the fluorouracil prodrugs/analogs capecitabine,<sup>1</sup> floxuridine,<sup>4</sup>, and tegafur.<sup>5,6</sup> A study in rats supports these reports, citing up to a 70-75% reduction in phenytoin metabolism in rats given fluorouracil or floxuridine.<sup>7</sup><br><br>The mechanism of this interaction appears to be fluorouracil-mediated inhibition of phenytoin p-hydroxylation, a process normally dependent on CYP2C9. Though neither floxuridine or fluorouracil appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>7,8</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>7</sup> and losartan/E3174 ratio<sup>9</sup>) following treatment with both floxuridine<sup>7</sup> and fluorouracil<sup>7,9</sup> treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>9</sup> Studies with the CYP2C9 substrate warfarin further support this.<sup>10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Brickell K, Porter D, Thompson P, “Phenytoin Toxicity Due to Fluoropyrimidines (5FU/Capecitabine): Three Case Reports,” <i>Br J Cancer</i>, 2003, 89(4):615-6.</p>\n<p>2. Gilbar PJ, Brodribb TR, “Phenytoin and Fluorouracil Interaction,” <i>Ann Pharmacother</i>, 2001, 35(11):1367-70.</p>\n<p>3. Rosemergy I, Findlay M, “Phenytoin Toxicity as a Result of 5-Fluorouracil Administration,” <i>N Z Med J</i>, 2002, 115(1159):U124.</p>\n<p>4. Konishi H, Morita K, Minouchi T, et al, “Probable Metabolic Interaction of Doxifluridine with Phenytoin,” <i>Ann Pharmacother</i>, 2002, 36(5):831-4.</p>\n<p>5. Tsuda A, Fujiyama J, Miki A, et al, “The First Case of Phenytoin Intoxication Associated with the Concomitant use of Phenytoin and TS-1, a Combination Preparation of Tegafur, Gimeracil, and Oteracil Potassium,” <i>Cancer Chemother Pharmacol</i>, 2008, 62(3):427-32.</p>\n<p>6. Wakisaka S, Shimauchi M, Kaji Y, et al, “Acute Phenytoin Intoxication Associated with the Antineoplastic Agent UFT,” <i>Fukuoka Igaku Zasshi</i>, 1990, 81(4):192-6.</p>\n<p>7. Konishi H, Yoshimoto T, Morita K, et al, “Depression of Phenytoin Metabolic Capacity by 5-Fluorouracil and Doxifluridine in Rats,” <i>J Pharm Pharmacol</i>, 2003, 55(1):143-9.</p>\n<p>8. Park JY, Kim KA, “Inhibitory Effect of 5-Fluorouracil on Human Cytochrome P(450) Isoforms in Human Liver Microsomes,” <i>Eur J Clin Pharmacol</i>, 2003, 59(5-6):407-9.</p>\n<p>9. Gunes A, Coskun U, Boruban C, et al, “Inhibitory Effect of 5-Fluorouracil on Cytochrome P450 2C9 Activity in Cancer Patients,” <i>Basic Clin Pharmacol Toxicol</i>, 2006, 98(2):197-200.</p>\n<p>10. Davis DA, Fugate SE, “Increasing Warfarin Dosage Reductions Associated with Concurrent Warfarin and Repeated Cycles of 5-Fluorouracil Therapy,” <i>Pharmacotherapy</i>, 2005, 25(3):442-7.</p>\n<p>11. Camidge R, Reigner B, Cassidy J, et al, “Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Cancer,” <i>J Clin Oncol</i>, 2005, 23(21):4719-25.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7619":"<p><b>Title</b> Fluorouracil (Systemic) / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Fluorouracil (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider the potential risks associated with using this combination when evaluating prolonged treatment with cimetidine in a patient receiving fluorouracil. If this combination is used, monitor patients extra closely for evidence of toxicity. Limited available data suggest short-duration cimetidine (i.e., single-dose or 1-week therapy) may be less likely to interact.</p> \n<p><b>Discussion</b> The fluorouracil AUC was increased by an average of 72% when oral fluorouracil was administered to patients with carcinoma (n=15) who had been pre-treated with cimetidine (1000 mg/day x 4 weeks).<sup>1</sup> The fluorouracil AUC was increased by an average of 27% when IV fluorouracil was similarly administered to patients pre-treated with cimetidine (1000 mg/day x 4 weeks).<sup>1</sup> Of note, pre-treatment with single-dose cimetidine (400 mg) or 1-week of cimetidine (1000 mg/day) both failed to significantly alter fluorouracil pharmacokinetics.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but inhibition of fluorouracil clearance by cimetidine and/or impaired liver blood flow are possible mechanisms that have been demonstrated and/or proposed.<sup>1</sup><br><br>Tegafur, floxuridine, and capecitabine are prodrugs that all yield fluorouracil as at least one of their active metabolites. As a result, all of these are similarly expected to have a possible interaction with cimetidine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvey VJ, Slevin ML, Dilloway MR, et al, “The Influence of Cimetidine on the Pharmacokinetics of 5-Fluorouracil,” <i>Br J Clin Pharmacol</i>, 1984, 18(3):421-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6487480\">[PubMed 6487480]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7620":"<p><b>Title</b> Tegafur / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase serum concentrations of the active metabolite(s) of Tegafur. Specifically, concentrations of fluorouracil may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider the potential risks associated with using this combination when evaluating prolonged treatment with cimetidine in a patient receiving tegafur. If this combination is used, monitor patients extra closely for evidence of toxicity. Limited available data suggest short-duration cimetidine (i.e., single-dose or 1-week therapy) may be less likely to interact.</p> \n<p><b>Discussion</b> The fluorouracil AUC was increased by an average of 72% when oral fluorouracil was administered to patients with carcinoma (n=15) who had been pre-treated with cimetidine (1000 mg/day x 4 weeks).<sup>1</sup> The fluorouracil AUC was increased by an average of 27% when IV fluorouracil was similarly administered to patients pre-treated with cimetidine (1000 mg/day x 4 weeks).<sup>1</sup> Of note, pre-treatment with single-dose cimetidine (400 mg) or 1-week of cimetidine (1000 mg/day) both failed to significantly alter fluorouracil pharmacokinetics.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but inhibition of fluorouracil clearance by cimetidine and/or impaired liver blood flow are possible mechanisms that have been demonstrated and/or proposed.<sup>1</sup><br><br>Tegafur, floxuridine, and capecitabine are prodrugs that all yield fluorouracil as at least one of their active metabolites. As a result, all of these are similarly expected to have a possible interaction with cimetidine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvey VJ, Slevin ML, Dilloway MR, et al, “The Influence of Cimetidine on the Pharmacokinetics of 5-Fluorouracil,” <i>Br J Clin Pharmacol</i>, 1984, 18(3):421-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6487480\">[PubMed 6487480]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7621":"<p><b>Title</b> Capecitabine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase serum concentrations of the active metabolite(s) of Capecitabine. Specifically, concentrations of fluorouracil may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider the potential risks associated with using this combination when evaluating prolonged treatment with cimetidine in a patient receiving capecitabine. If this combination is used, monitor patients extra closely for evidence of toxicity. Limited available data suggest short-duration cimetidine (i.e., single-dose or 1-week therapy) may be less likely to interact.</p> \n<p><b>Discussion</b> The fluorouracil AUC was increased by an average of 72% when oral fluorouracil was administered to patients with carcinoma (n=15) who had been pre-treated with cimetidine (1000 mg/day x 4 weeks).<sup>1</sup> The fluorouracil AUC was increased by an average of 27% when IV fluorouracil was similarly administered to patients pre-treated with cimetidine (1000 mg/day x 4 weeks).<sup>1</sup> Of note, pre-treatment with single-dose cimetidine (400 mg) or 1-week of cimetidine (1000 mg/day) both failed to significantly alter fluorouracil pharmacokinetics.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but inhibition of fluorouracil clearance by cimetidine and/or impaired liver blood flow are possible mechanisms that have been demonstrated and/or proposed.<sup>1</sup><br><br>Tegafur, floxuridine, and capecitabine are prodrugs that all yield fluorouracil as at least one of their active metabolites. As a result, all of these are similarly expected to have a possible interaction with cimetidine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvey VJ, Slevin ML, Dilloway MR, et al, “The Influence of Cimetidine on the Pharmacokinetics of 5-Fluorouracil,” <i>Br J Clin Pharmacol</i>, 1984, 18(3):421-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6487480\">[PubMed 6487480]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7622":"<p><b>Title</b> Floxuridine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase serum concentrations of the active metabolite(s) of Floxuridine. Specifically, concentrations of fluorouracil may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider the potential risks associated with using this combination when evaluating prolonged treatment with cimetidine in a patient receiving floxuridine. If this combination is used, monitor patients extra closely for evidence of toxicity. Limited available data suggest short-duration cimetidine (i.e., single-dose or 1-week therapy) may be less likely to interact.</p> \n<p><b>Discussion</b> The fluorouracil AUC was increased by an average of 72% when oral fluorouracil was administered to patients with carcinoma (n=15) who had been pre-treated with cimetidine (1000 mg/day x 4 weeks).<sup>1</sup> The fluorouracil AUC was increased by an average of 27% when IV fluorouracil was similarly administered to patients pre-treated with cimetidine (1000 mg/day x 4 weeks).<sup>1</sup> Of note, pre-treatment with single-dose cimetidine (400 mg) or 1-week of cimetidine (1000 mg/day) both failed to significantly alter fluorouracil pharmacokinetics.<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain, but inhibition of fluorouracil clearance by cimetidine and/or impaired liver blood flow are possible mechanisms that have been demonstrated and/or proposed.<sup>1</sup><br><br>Tegafur, floxuridine, and capecitabine are prodrugs that all yield fluorouracil as at least one of their active metabolites. As a result, all of these are similarly expected to have a possible interaction with cimetidine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvey VJ, Slevin ML, Dilloway MR, et al, “The Influence of Cimetidine on the Pharmacokinetics of 5-Fluorouracil,” <i>Br J Clin Pharmacol</i>, 1984, 18(3):421-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6487480\">[PubMed 6487480]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7623":"<p><b>Title</b> Lubiprostone / Methadone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methadone may diminish the therapeutic effect of Lubiprostone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced effects of lubiprostone in patients receiving methadone.</p> \n<p><b>Discussion</b> In vitro studies indicate a potential for methadone to reduce lubiprostone mediated activation of ClC-2 chloride channels.<sup>1,2,3</sup> Based on this, lubiprostone U.S. prescribing information warns about the potential for reduced lubiprostone therapeutic effects in patients receiving any diphenylheptane opioid.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Amitiza (lubiprostone). Bethesda, MD: Sucampo Pharma Americas, LLC, April 2013.</p>\n<p>2. Cuppoletti J, Blikslager AT, Chakrabarti J, et al, “Contrasting Effects of Linaclotide and Lubiprostone on Restitution of Epithelial Cell Barrier Properties and Cellular Homeostasis After Exposure to Cell Stressors,” <i>BMC Pharmacol</i>, 2012, 12:3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22553939\">[PubMed 22553939]</a></p>\n<p>3. Cuppoletti J, Chakrabarti J, Tewari K, et al, “Methadone but not Morphine Inhibits Lubiprostone-Stimulated Cl- Currents in T84 Intestinal Cells and Recombinant Human ClC-2, but not CFTR Cl- Currents,” <i>Cell Biochem Biophys</i>, 2013, 66(1):53-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22918821\">[PubMed 22918821]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7624":"<p><b>Title</b> Sulpiride / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Sulpiride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Separate administration of antacids and sulpiride by at least 2 hours in order to minimize the impact of antacids on sulpiride absorption.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> According to the sulpiride summary of product characteristics, antacids reduce the absorption of sulpiride.<sup>1,2,3</sup> As a result, it is recommended that antacids and sulpiride be administered at least 2 hours apart from one another in order to minimize the potential for any significant interaction.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p>2. Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013.</p>\n<p>3. Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7625":"<p><b>Title</b> Sulpiride / Sucralfate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sucralfate may decrease the serum concentration of Sulpiride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Separate administration of sucralfate and sulpiride by at least 2 hours in order to minimize the impact of sucralfate on sulpiride absorption.</p> \n<p><b>Discussion</b> According to the sulpiride summary of product characteristics, sucralfate reduces the absorption of sulpiride.<sup>1,2,3</sup> As a result, it is recommended that sucralfate and sulpiride be administered at least 2 hours apart from one another in order to minimize the potential for any significant interaction.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p>2. Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013.</p>\n<p>3. Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7626":"<p><b>Title</b> Neuromuscular-Blocking Agents / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for enhanced and/or prolonged neuromuscular blockade in patients receiving cyclosporine.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> Several published case reports describe signs of apparent enhanced or prolonged neuromuscular blockade in patients receiving neuromuscular blocking agents (NMBs; vecuronium, pancuronium) during treatment with cyclosporine.<sup>1,2,3</sup> Additionally, in a retrospective review of records from patients who experienced NMB (vecuronium or atracurium) associated respiratory failure or prolonged neuromuscular blockade, 8 patients were also receiving cyclosporine.<sup>4</sup> The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ganjoo P and Tewari P, “Oral Cyclosporine-Vecuronium Interaction,” <i>Can J Anaesth</i>, 1994, 41(10):1017. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8001203\">[PubMed 8001203]</a></p>\n<p>2. Wood GG, “Cyclosporine-Vecuronium Interaction,” <i>Can J Anaesth</i>, 1989, 36(3 Pt 1):358. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2566392\">[PubMed 2566392]</a></p>\n<p>3. Crosby E and Robblee JA, “Cyclosporine-Pancuronium Interaction in a Patient With a Renal Allograft,” <i>Can J Anaesth</i>, 1988, 35(3 ( Pt 1)):300-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3289771\">[PubMed 3289771]</a></p>\n<p>4. Sidi A, Kaplan RF and Davis RF, “Prolonged Neuromuscular Blockade and Ventilatory Failure After Renal Transplantation and Cyclosporine,” <i>Can J Anaesth</i>, 1990, 37(5):543-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1973635\">[PubMed 1973635]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7628":"<p><b>Title</b> Sulpiride / Antipsychotic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of sulpiride with other antipsychotics.</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> According to the sulpiride summary of product characteristics, concurrent use with other antipsychotics should be avoided.<sup>1,2,3</sup><br><br>Though the specific concern is not stated, it is expected that such combinations could increase the risk for clinically significant antipsychotic adverse effects/toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p>2. Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013.</p>\n<p>3. Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7629":"<p><b>Title</b> Sulpiride / Cabergoline</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The strength of this warning varies according to the country in which the sulpiride product was approved and marketed.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cabergoline may diminish the therapeutic effect of Sulpiride. Sulpiride may diminish the therapeutic effect of Cabergoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of sulpiride and cabergoline. This combination is specifically contraindicated by some, but not all, sulpiride brands.</p> \n<p><b>Discussion</b> According to the summary of product characteristics for at least some sulpiride brands, concurrent use with the dopamine agonists cabergoline or quinagolide is contraindicated;<sup>1</sup> however, some list the combination as not recommended or don't specifically mention the combination at all.<sup>2,3</sup><br><br>The concern with the combination is that cabergoline or quinagolide (dopamine receptor agonists) and sulpiride (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</p>\n<p>2. Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p>3. Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7630":"<p><b>Title</b> Sulpiride / Quinagolide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The strength of this warning varies according to the country in which the sulpiride product was approved and marketed.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Quinagolide may diminish the therapeutic effect of Sulpiride. Sulpiride may diminish the therapeutic effect of Quinagolide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of sulpiride and quinagolide. This combination is specifically contraindicated by some, but not all, sulpiride brands.</p> \n<p><b>Discussion</b> According to the summary of product characteristics for at least some sulpiride brands, concurrent use with the dopamine agonists cabergoline or quinagolide is contraindicated;<sup>1</sup> however, some list the combination as not recommended or don't specifically mention the combination at all.<sup>2,3</sup><br><br>The concern with the combination is that cabergoline or quinagolide (dopamine receptor agonists) and sulpiride (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</p>\n<p>2. Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p>3. Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7633":"<p><b>Title</b> Sulpiride / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Sulpiride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid concurrent use of sulpiride and alcohol. Any combined use can be expected to enhance the sedative and impaired reaction effects of both drugs.</p> \n<p><b>Discussion</b> According to the summary of product characteristics for several sulpiride brands, concurrent use with alcohol is not recommended and should be avoided.<sup>1,2,3</sup> <br><br>The concern with the combination is that the sedative and impaired reaction effects of these drugs may be enhanced.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Dolmatil (sulpiride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p>2. Summary of product characteristics. Sulpor (sulpiride). Leeds, United Kingdom: Rosemont Pharmaceuticals Ltd, 04/2013.</p>\n<p>3. Summary of product characteristics. Dogmatil (sulpiride). Quetigny, France: Sanofi Winthrop Industrie, 04/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7634":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inducers) / Dabrafenib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dabrafenib may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor closely for diminished therapeutic effects of most substrates. The nature and clinical impact of this interaction on CYP3A4 substrates that are converted to active metabolites are unknown and likely to vary by substrate.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inducers) Interacting Members</b> Abemaciclib, Abiraterone Acetate, Acalabrutinib, Alfuzosin, ALPRAZolam, Amiodarone, AmLODIPine, Apixaban, Apremilast, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Armodafinil, Artemether, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Bedaquiline, Benidipine, Benzhydrocodone, Benzphetamine, Bisoprolol, Blonanserin, Boceprevir, Bortezomib, Bosutinib, Brexpiprazole, Brigatinib, Bromperidol, Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Citalopram, Clarithromycin, ClonazePAM, Clorazepate, Cobicistat, Cobimetinib, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Daclatasvir, Dantrolene, Dapsone (Systemic), Darifenacin, Darunavir, Dasabuvir, Dasatinib, Deflazacort, Delavirdine, Dexamethasone (Systemic), DiazePAM, Dienogest, Digitoxin, DilTIAZem, Disopyramide, DOCEtaxel, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Efavirenz, Elbasvir, Eliglustat, Elvitegravir, Enzalutamide, Eplerenone, Erlotinib, Erythromycin (Systemic), Escitalopram, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Eszopiclone, Ethinyl Estradiol, Ethosuximide, Etizolam, Etoposide, Etoposide Phosphate, Etoricoxib, Etravirine, Everolimus, Exemestane, Felbamate, Felodipine, Fesoterodine, Flibanserin, Flurazepam, Fosamprenavir, Fosaprepitant, Gefitinib, Gemigliptin, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Idelalisib, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ixazomib, Ketoconazole (Systemic), Lacidipine, Lansoprazole, Lapatinib, Lercanidipine, Levonorgestrel (Systemic), Lidocaine (Systemic), Linagliptin, Lomitapide, Losartan, Lovastatin, Lumefantrine, Lurasidone, Lynestrenol, Macimorelin, Macitentan, Manidipine, Maraviroc, MedroxyPROGESTERone, Mefloquine, Mestranol, Methadone, Mianserin, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Modafinil, Naldemedine, Naloxegol, Nefazodone, Nelfinavir, Neratinib, Netupitant, Nevirapine, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Norethindrone, Norgestrel, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Ondansetron, Osimertinib, Ospemifene, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Perampanel, Pimozide, Piperaquine, Pipotiazine, Praziquantel, Primaquine, Progesterone, QUEtiapine, QuiNIDine, QuiNINE, RABEprazole, Radotinib, Ranolazine, Regorafenib, Repaglinide, Ribociclib, Rifabutin, Rilpivirine, Riociguat, Ritonavir, Rivaroxaban, Roflumilast, Rolapitant, RomiDEPsin, Saquinavir, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tamoxifen, Tamsulosin, Tasimelteon, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tetracycline (Systemic), Tezacaftor, TiaGABine, Tibolone, Ticagrelor, Ticlopidine, Tipranavir, Tofacitinib, Tolterodine, Tolvaptan, Toremifene, Trabectedin, TraMADol, TraZODone, Triazolam, Trimethoprim, Trimipramine, Ulipristal, Valbenazine, Vandetanib, Velpatasvir, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, Vilazodone, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vortioxetine, Voxilaprevir, Zolpidem, Zonisamide, Zopiclone</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in dabrafenib US prescribing information, coadministration of dabrafenib decreased the maximum concentration and AUC of midazolam by 61% and 74%, respectively.<sup>1</sup> A case report describes a 47-year-old man who experienced a decrease in everolimus serum concentrations (3.75 ng/mL to 1.37 ng/mL) and a decrease in tacrolimus serum concentrations (6.8 ng/mL to less than 2 ng/mL) one month after initiation of dabrafenib.<sup>2</sup> The everolimus dose was increased over 6-fold and the tacrolimus dose was increased 2.4-fold to maintain levels in therapeutic range.<sup>2</sup> <br><br>The suspected primary mechanism of this interaction is dabrafenib induction of CYP3A4-mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tafinlar (dabrafenib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2013.</p>\n<p>2. Levavasseur M, Darras S, Mortier L, Goeminne C, Auffret M, Bertrand M. Drug interaction between dabrafenib and immunosuppressive drugs: about one case [published online July 8, 2016]. <i>Melanoma Res</i>. doi: 10.1097/CMR.0000000000000280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27399255\">[PubMed 27399255]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7635":"<p><b>Title</b> CYP2C8 Substrates (High risk with Inducers) / Dabrafenib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dabrafenib may decrease the serum concentration of CYP2C8 Substrates (High risk with Inducers). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Seek alternatives to the CYP2C8 substrate when possible. If concomitant therapy cannot be avoided, monitor closely for diminished therapeutic effects of most substrates. The nature and clinical impact of this interaction on CYP2C8 substrates that are converted to active metabolites are unknown and likely to vary by substrate.</p>\n<div>\n <p><b>CYP2C8 Substrates (High risk with Inducers) Interacting Members</b> Amiodarone, Dabrafenib, Dasabuvir, Enzalutamide, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Pioglitazone, Repaglinide, Rosiglitazone, Velpatasvir</p>\n</div> \n<p><b>Discussion</b> Dabrafenib U.S. prescribing information states that dabrafenib may induce a variety of CYP-450 isoforms, including CYPs 2B6, 2C8, 2C9, 2C19, and 3A4.<sup>1</sup> Due to the theoretical potential for diminished systemic concentrations of substrates of these pathways, dabrafenib prescribing information recommends that alternatives to the substrates be sought in patients treated with dabrafenib, or that patients be closely monitored for diminished substrate effects.<sup>1</sup> The impact of dabrafenib induction of CYP2C8 has not been specifically studied clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tafinlar (dabrafenib). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7636":"<p><b>Title</b> CYP2C9 Substrates (High risk with Inducers) / Dabrafenib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dabrafenib may decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Seek alternatives to the CYP2C9 substrate when possible. If concomitant therapy cannot be avoided, monitor closely for diminished therapeutic effects of most substrates. The nature and clinical impact of this interaction on CYP2C9 substrates that are converted to active metabolites are unknown and likely to vary by substrate.</p>\n<div>\n <p><b>CYP2C9 Substrates (High risk with Inducers) Interacting Members</b> Acenocoumarol, Benzbromarone, Celecoxib, ChlorproPAMIDE, Dapsone (Systemic), Etravirine, FLUoxetine, Fosphenytoin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Ketamine, Lesinurad, Losartan, Meloxicam, Mestranol, Nateglinide, Ospemifene, Phenytoin, Piroxicam (Systemic), SulfADIAZINE, Sulfamethoxazole, Sulfinpyrazone, SulfiSOXAZOLE, Tamoxifen, TOLBUTamide, Torsemide, Trimethoprim, Voriconazole, Warfarin, Zafirlukast</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in dabrafenib US prescribing information, coadministration of dabrafenib (150 mg twice daily) decreased the AUC of the S-isomer of warfarin (following a 15 mg single dose of the racemate) by 37%.<sup>1,2</sup> The suspected primary mechanism of this interaction is dabrafenib induction of CYP2C9 mediated S-warfarin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tafinlar (dabrafenib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2014.</p>\n<p>2. Suttle AB, Grossman KF, Ouellet D, et al. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. <i>J Clin Pharmacol</i>. 2015;55(4):392-400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25449654\">[PubMed 25449654]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7637":"<p><b>Title</b> CYP2C19 Substrates (High risk with Inducers) / Dabrafenib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dabrafenib may decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Seek alternatives to the CYP2C19 substrate when possible. If concomitant therapy cannot be avoided, monitor closely for diminished therapeutic effects of most substrates. The nature and clinical impact of this interaction on CYP2C19 substrates that are converted to active metabolites are unknown and likely to vary by substrate.</p>\n<div>\n <p><b>CYP2C19 Substrates (High risk with Inducers) Interacting Members</b> Bortezomib, Brivaracetam, Carisoprodol, Citalopram, CloBAZam, ClomiPRAMINE, Desogestrel, DiazePAM, Dydrogesterone, Escitalopram, Esomeprazole, Etizolam, Etravirine, Fosphenytoin, Imipramine, Lansoprazole, Methsuximide, Moclobemide, Nelfinavir, Nilutamide, Omeprazole, Pantoprazole, PHENobarbital, Phenytoin, Progesterone, RABEprazole, Stiripentol, Trimipramine, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Dabrafenib U.S. prescribing information states that dabrafenib may induce a variety of CYP-450 isoforms, including CYPs 2B6, 2C8, 2C9, 2C19, and 3A4.<sup>1</sup> Due to the theoretical potential for diminished systemic concentrations of substrates of these pathways, dabrafenib prescribing information recommends that alternatives to the substrates be sought in patients treated with dabrafenib, or that patients be closely monitored for diminished substrate effects.<sup>1</sup> The impact of dabrafenib induction of CYP2C19 has not been specifically studied clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tafinlar (dabrafenib). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7638":"<p><b>Title</b> CYP2B6 Substrates (High risk with Inducers) / Dabrafenib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dabrafenib may decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased effect/therapeutic failure of CYP2B6 substrates (or increased effects if CYP2B6 is responsible for conversion of a prodrug to its active metabolite [eg, cyclophosphamide]) if combined with dabrafenib.</p>\n<div>\n <p><b>CYP2B6 Substrates (High risk with Inducers) Interacting Members</b> BuPROPion, Cyclophosphamide, Efavirenz, Ifosfamide, Methadone, Selegiline, Velpatasvir</p>\n</div> \n<p><b>Discussion</b> Dabrafenib prescribing information states that concomitant use of sensitive CYP2B6 substrates and dabrafenib may lead to decreased efficacy of the CYP2B6 substrate.<sup>1</sup> In vitro data indicate that dabrafenib may induce CYP2B6,<sup>1</sup> but no studies have been conducted to assess the potential for dabrafenib to decrease serum concentrations of CYP2B6 substrates in humans.<sup>1</sup> Monitoring for decreased effects and therapeutic failure of CYP2B6 substrates is recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tafinlar (dabrafenib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7639":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Dabrafenib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dabrafenib may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Females of reproductive potential should use an alternative, highly effective, non-hormonal means of contraception during and at least 2 weeks (dabrafenib alone) or 4 months (dabrafenib + trametinib) after discontinuation of dabrafenib treatment.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Dabrafenib U.S. prescribing information recommends that females of reproductive potential use an alternative, highly effective, non-hormonal means of contraception during and at least 2 weeks (dabrafenib alone) or 4 months (dabrafenib + trametinib) after discontinuation of dabrafenib treatment.<sup>1</sup> Dabrafenib may induce the major metabolic pathways of estrogens and progestins used for contraception (e.g., CYP3A4), thereby potentially reducing their efficacy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tafinlar (dabrafenib). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7640":"<p><b>Title</b> Progestins (Contraceptive) / Dabrafenib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dabrafenib may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Females of reproductive potential should use an alternative, highly effective, non-hormonal means of contraception during and at least 2 weeks (dabrafenib alone) or 4 months (dabrafenib + trametinib) after discontinuation of dabrafenib treatment.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Dabrafenib U.S. prescribing information recommends that females of reproductive potential use an alternative, highly effective, non-hormonal means of contraception during and at least 2 weeks (dabrafenib alone) or 4 months (dabrafenib + trametinib) after discontinuation of dabrafenib treatment.<sup>1</sup> Dabrafenib may induce the major metabolic pathways of estrogens and progestins used for contraception (e.g., CYP3A4), thereby potentially reducing their efficacy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tafinlar (dabrafenib). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7641":"<p><b>Title</b> Dabrafenib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Dabrafenib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to St. John's wort when possible. If concomitant therapy cannot be avoided, monitor closely for diminished therapeutic effects of dabrafenib.</p> \n<p><b>Discussion</b> St. John's wort is capable of inducing CYP3A4, one of the major enzymes responsible for metabolism of dabrafenib and some of its metabolites.<sup>1</sup> Due to the potential for diminished systemic concentrations and effects of dabrafenib in patients receiving St. John's wort, dabrafenib U.S. prescribing information recommends that alternatives to St. John's wort be sought in patients treated with dabrafenib, or that patients be closely monitored for diminished effects of dabrafenib.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tafinlar (dabrafenib). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7642":"<p><b>Title</b> Dabrafenib / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Dabrafenib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced efficacy of dabrafenib in patients who take antacids. Carefully consider the need for treatment with the antacid in light of this potential. Separating doses of these agents by the maximum amount of time possible could theoretically reduce the magnitude of interaction, but this strategy has not been studied clinically.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Dabrafenib U.S. prescribing information states that coadministration with drugs that increase the pH of the upper gastrointestinal tract (e.g., antacids, histamine H2-antagonists, proton pump inhibitors) may alter the solubility of dabrafenib and reduce its absorption.<sup>1</sup> The magnitude and clinical significance of this possible interaction have not been studied. Dabrafenib is very slightly soluble at pH 1, and practically insoluble above pH 4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tafinlar (dabrafenib). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7643":"<p><b>Title</b> Dabrafenib / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Dabrafenib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced efficacy of dabrafenib in patients who take histamine H2-antagonists. Carefully consider the need for treatment with the histamine H2-antagonist in light of this potential.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> Dabrafenib U.S. prescribing information states that coadministration with drugs that increase the pH of the upper gastrointestinal tract (e.g., antacids, histamine H2-antagonists, proton pump inhibitors) may alter the solubility of dabrafenib and reduce its absorption.<sup>1</sup> The magnitude and clinical significance of this possible interaction have not been studied. Dabrafenib is very slightly soluble at pH 1, and practically insoluble above pH 4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tafinlar (dabrafenib). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7644":"<p><b>Title</b> Dabrafenib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Proton Pump Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Seek alternatives to proton pump inhibitors in patients treated with dabrafenib. Monitor patients receiving these combinations closely for reduced efficacy of dabrafenib and the proton pump inhibitor.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> Dabrafenib U.S. prescribing information states that coadministration with drugs that increase the pH of the upper gastrointestinal tract (e.g., antacids, histamine H2-antagonists, proton pump inhibitors) may alter the solubility of dabrafenib and reduce its absorption.<sup>1</sup> The magnitude and clinical significance of this possible interaction have not been studied. Dabrafenib is very slightly soluble at pH 1, and practically insoluble above pH 4.<sup>1</sup> <br><br>In addition to the possible pH related interaction between these agents, dabrafenib may induce a variety of CYP-450 isoforms, including CYPs 2B6, 2C8, 2C9, 2C19, and 3A4.<sup>1</sup> The proton pump inhibitors included in this monograph are all substrates of these isoforms, particularly CYP2C19. Due to the theoretical potential for diminished systemic concentrations of substrates of these pathways, dabrafenib prescribing information recommends that alternatives to substrates of these enzymes be sought in patients treated with dabrafenib, or that patients be closely monitored for diminished substrate effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tafinlar (dabrafenib). Research Triangle Park, NC: GlaxoSmithKline, May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7645":"<p><b>Title</b> Warfarin / Atovaquone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atovaquone may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor anticoagulant response (e.g., INR and signs/symptoms of bleeding) to warfarin closely following the addition or cessation of concurrent atovaquone.</p> \n<p><b>Discussion</b> A 53-year-old man taking warfarin who was at a therapeutic INR experienced an increased INR (from 2.3 to 3.5) 7 days after starting atovaquone 1500 mg/day.<sup>1</sup> A 5% reduction in the weekly warfarin dose failed to achieve a therapeutic INR (values remained at 3.1-4.2 over the next 4-5 weeks), necessitating an additional warfarin dose reduction.<br><br>The mechanism of this possible interaction is unclear, but it has been proposed that atovaquone, which is highly protein-bound, may be displacing warfarin from its protein binding sites and increasing free concentrations of the drug.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hidalgo K, Lyles A, Dean SR, “A Potential Interaction between Warfarin and Atovaquone,” <i>Ann Pharmacother</i>, 2011, 45(1):e3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21189363\">[PubMed 21189363]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7646":"<p><b>Title</b> Alcohol (Ethyl) / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Efavirenz may enhance the adverse/toxic effect of Alcohol (Ethyl). Efavirenz may decrease the serum concentration of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Note that the intoxicating effects of alcohol may be disproportionately greater than indicated by the blood alcohol concentration for patients being treated with efavirenz. Patients should be advised to use extra caution with any alcohol consumption if they are taking efavirenz due to the potential for increased central nervous system effects.</p> \n<p><b>Discussion</b> Reduced blood alcohol concentrations, but with no change in intoxicating effects, were reported in a study of 18 male and 2 female subjects with untreated HIV disease who were assigned to either ritonavir (n=10) or efavirenz (n=10) (x 2 weeks) with either 1 g/kg alcohol drink or placebo.<sup>1</sup> Blood samples and neuropsychological measures were taken at predetermined times, starting before alcohol consumption and continuing 8 hours after. This observed lack of a reduction in intoxicating effects despite the reduction in alcohol concentration was interpreted as a relative increase in alcohol-related intoxication. These results build upon previous work by the same group, in which reduced blood alcohol concentration without any corresponding decrease in subjective intoxicating effects were reported following initiation of antiretroviral therapy.<sup>2</sup><br><br>The specific mechanism(s) responsible for this possible interaction is (are) unclear. Enzyme induction by efavirenz and/or selected other antiretroviral drugs may explain, at least in part, the reduced alcohol concentrations. Efavirenz has also been associated with intoxicating-like psychoactive effects.<sup>3</sup> The prescribing information for efavirenz warns of possible additive central nervous system effects when given with alcohol or other psychoactive drugs.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. McCance-Katz EF, Gruber VA, Rainey PM, et al, “Interactions Between Alcohol and the Antiretroviral Medications Ritonavir or Efavirenz,” <i>J Addict Med</i>, 2013, May 9 (epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23666322\">[PubMed 23666322]</a></p>\n<p>2. McCance-Katz EF, Lum PJ, Rainey PM, et al, “Untreated HIV Infection is Associated with Higher Blood Alcohol Levels,” <i>J Acquir Immune Defic Syndr</i>, 2012, 60(3):282-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22495786\">[PubMed 22495786]</a></p>\n<p>3. Gatch MB, Gonzalez Maeso J, Schetz JA, et al, “The HIV Antiretroviral Drug Efavirenz Has LSD-like Properties,” <i>Neuropsychopharmacology</i>, 2013, May 24 (epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23702798\">[PubMed 23702798]</a></p>\n<p>4. Prescribing information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb Company, May 2013.</p>\n<p>5. Prescribing information. Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate). Foster City, CA: Bristol-Myers Squibb &amp; Gilead Sciences, LLC., April 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7647":"<p><b>Title</b> Vaccines (Live) / Dimethyl Fumarate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Product labeling in Canada, but not in the U.S., recommends avoiding live attenuated vaccines during dimethyl fumarate treatment.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dimethyl Fumarate may enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Canadian labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment. U.S. labeling does not mention this.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> Dimethyl fumarate Canadian labeling states that administration of live attenuated vaccines is not recommended during treatment due to the theoretical potential for infection and reduced immune response to the vaccine.<sup>1</sup> U.S. labeling, in contrast, does not discuss this possibility.<sup>2</sup> Dimethyl fumarate use is associated with a sustained decrease in lymphocyte counts, which could decrease the immune response to vaccination and increase the likelihood of vaccinal infection. Rates of infection and serious infection were similar in patients treated with dimethyl fumarate or placebo in initial clinical trials.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Tecfidera (dimethyl fumarate). Mississauga, ON: Biogen Idec Canada Inc., March 2013.</p>\n<p>2. Prescribing information. Tecfidera (dimethyl fumarate). Cambridge, MA: Biogen Idec Inc., 3/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7648":"<p><b>Title</b> Alcohol (Ethyl) / Amisulpride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amisulpride may enhance the adverse/toxic effect of Alcohol (Ethyl). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid concurrent use of amisulpride and alcohol. Any combined use can be expected to enhance the sedative and impaired reaction effects of both drugs.</p> \n<p><b>Discussion</b> According to the amisulpride summary of product characteristics, concurrent use with alcohol is not recommended and should be avoided.<sup>1,2</sup><br><br>The concern with the combination is that the sedative and impaired reaction effects of these drugs may be enhanced.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Solian (amisulpride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p>2. Summary of product characteristics. Solian (amisulpride). Quetigny, France: Sanofi Winthrop Industrie, November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7649":"<p><b>Title</b> Amisulpride / Antipsychotic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of amisulpride with other antipsychotics should be avoided.</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> According to the amisulpride summary of product characteristics, concurrent use with other antipsychotics should be avoided.<sup>1,2</sup><br><br>Though the specific concern is not stated, it is expected that such combinations could increase the risk for clinically significant antipsychotic adverse effects/toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Solian (amisulpride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p>2. Summary of product characteristics. Solian (amisulpride). Quetigny, France: Sanofi Winthrop Industrie, November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7650":"<p><b>Title</b> Anti-Parkinson Agents (Dopamine Agonist) / Amisulpride</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The specific contraindications vary between Singapore and UK amisulpride summary of product characteristics.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amisulpride may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of amisulpride and levodopa is contraindicated. In addition, concurrent use of amisulpride with other dopamine agonists is contraindicated for some, but not all, amisulpride brands.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Dopamine Agonist) Interacting Members</b> Amantadine, Apomorphine, Bromocriptine, Levodopa, Pergolide, Piribedil, Pramipexole, ROPINIRole, Rotigotine</p>\n</div> \n<p><b>Discussion</b> According to the summary of product characteristics (SPC) for amisulpiride, concurrent use with the dopamine agonist levodopa is contraindicated.<sup>1,2</sup> In addition, the Singapore SPC for amisulpride also contraindicates concurrent use with any dopamine agonist.<sup>2</sup><br><br>The concern with the combination is that levodopa (a dopamine precursor/dopamine receptor agonist) or other dopamine agonists and amisulpride (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Solian (amisulpride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p>2. Summary of product characteristics. Solian (amisulpride). Quetigny, France: Sanofi Winthrop Industrie, November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7651":"<p><b>Title</b> Simvastatin / Alitretinoin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Alitretinoin (Systemic) may decrease the serum concentration of Simvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Simvastatin AUC and maximum serum concentration (Cmax) were reduced by an average of 16% and 23%, respectively, with concurrent alitretinoin in a study of 18 healthy male volunteers who were given alitretinoin 30 mg with simvastatin 40 mg.<sup>1</sup><br><br>Although the alitretinoin product monograph indicates that the slight reduction in simvastatin concentrations may require dose adjustment of simvastatin during routine cholesterol monitoring, if necessary, the slight decrease in simvastatin concentrations are unlikely to be clinically relevant.<sup>1,2</sup><br><br>At higher than proposed clinical dosing alitretinoin has been shown to induce CYP450 enzymes, which may be a possible mechanism for this interaction.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schmitt-Hoffmann AH, Roos B, Meyer I, et al, “Pharmacokinetic Interactions between Alitretinoin and Ketoconazole or Simvastatin or Ciclosporin A,” <i>Clin Exp Dermatol</i>, 2011, 36 (Suppl 2):24-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21443601\">[PubMed 21443601]</a></p>\n<p>2. Prescribing information. Toctino (alitretinoin). Mississauga, Ontario, Canada: GlaxoSmithKline Inc., January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7652":"<p><b>Title</b> Methotrexate / Alitretinoin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alitretinoin (Systemic) may enhance the hepatotoxic effect of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of liver dysfunction more closely in patients using both systemic alitretinoin and methotrexate in combination.</p> \n<p><b>Discussion</b> The product monograph for alitretinoin states that transient reversible increases in liver transaminases have been seen with systemic retinoids and cautions that the risk of liver toxicity may be increased if taken with methotrexate.<sup>1</sup><br><br>The combination of the retinoid etretinate and methotrexate has been associated with an increased risk of hepatitis.<sup>2,3,4</sup> The prescribing information for acitretin, a metabolite of etretinate and an available retinoid drug product, states that its use is contraindicated with methotrexate.<sup>2</sup> There are no published clinical reports or studies that specifically mention an interaction between alitretinoin and methotrexate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Toctino (alitretinoin). Mississauga, Ontario, Canada: GlaxoSmithKline Inc., January 2013.</p>\n<p>2. Prescribing information. Soriatane (Acitretin). Research Triangle Park, NC: Stiefel Laboratories, Inc., March 2011.</p>\n<p>3. Zachariae H, “Dangers of Methotrexate/Etretinate Combination Therapy,” <i>Lancet</i>, 1988, 20(1):422. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2893228\">[PubMed 2893228]</a></p>\n<p>4. Beck HI, Foged EK, “Toxic Hepatitis Due to Combination Therapy with Methotrexate and Etretinate in Psoriasis,” <i>Dermatologica</i>, 1983, 167(2):94-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6628806\">[PubMed 6628806]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7653":"<p><b>Title</b> Anticoagulants / Tibolone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tibolone may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced effects of anticoagulant agents when used in combination with tibolone. Consider the prospective benefits of tibolone treatment in light of this potential risk.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> The tibolone U.K. summary of product characteristics recommends cautious use in combination with anticoagulants because the fibrinolytic actions of tibolone may enhance anticoagulation.<sup>1</sup> In a clinical study of postmenopausal women, coadministration of tibolone (2.5 mg/day for 21 days) following stabilization on warfarin (baseline INR 1.4-2) increased INR by 0.4 on average and decreased circulating concentrations of factors II, VII, VIIa and X compared to placebo.<sup>1,2,</sup> A published report also describes several cases in which tibolone initiation in warfarin treated patients was associated with increased INR and decreased warfarin dose requirements.<sup>3</sup> These results contrast somewhat with a previous study that found a lack of impact of tibolone alone on prothrombin time and factors VII, VIII and X.<sup>4</sup> Numerous other investigations, however, consistently suggest a potential for tibolone to enhance anticoagulant effects, via enhancement of fibrinolytic activity and/or decreasing coagulation factor concentrations or function.<sup>4,5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Livial (tibolone). Hertfordshire, UK: Merck Sharp &amp; Dohme Limited, 2/2013.</p>\n<p>2. Elbers J, Hageluken C and Wadham A, “Tibolone (Livial) Enhances Warfarin-Induced Anticoagulation in Postmenopausal Women,” <i>Maturitas</i>, 2007, 56(1):94-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16887301\">[PubMed 16887301]</a></p>\n<p>3. McLintock LA, Dykes A, Tait RC, et al, “Interaction Between Hormone Replacement Therapy Preparations and Oral Anticoagulant Therapy,” <i>BJOG</i>, 2003, 110(8):777-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12892692\">[PubMed 12892692]</a></p>\n<p>4. Cortes-Prieto J, “Coagulation and Fibrinolysis in Post-Menopausal Women Treated With Org OD 14,” <i>Maturitas</i>, 1987, Suppl 1:67-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3306292\">[PubMed 3306292]</a></p>\n<p>5. Winkler UH, Altkemper R, Kwee B, et al, “Effects of Tibolone and Continuous Combined Hormone Replacement Therapy on Parameters in the Clotting Cascade: A Multicenter, Double-Blind, Randomized Study,” <i>Fertil Steril</i>, 2000, 74(1):10-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10899490\">[PubMed 10899490]</a></p>\n<p>6. Perrone G, Capri O, Galoppi P, et al, “Effects of Either Tibolone or Continuous Combined Transdermal Estradiol With Medroxyprogesterone Acetate on Coagulatory Factors and Lipoprotein(a) in Menopause,” <i>Gynecol Obstet Invest</i>, 2009, 68(1):33-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19349712\">[PubMed 19349712]</a></p>\n<p>7. Eilertsen AL, Sandvik L, Mowinckel MC, et al, “Differential Effects of Conventional and Low Dose Oral Hormone Therapy (HT), Tibolone, and Raloxifene on Coagulation and Fibrinolysis,” <i>Thromb Res</i>, 2007, 120(3):371-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17156824\">[PubMed 17156824]</a></p>\n<p>8. Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, et al, “Effect of Different Preparations of Hormone Therapy on Lipid and Glucose Metabolism, Coagulation Factors, and Bone Mineral Density in Overweight and Obese Postmenopausal Women,” <i>Fertil Steril</i>, 2005, 84(2):384-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16084879\">[PubMed 16084879]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7654":"<p><b>Title</b> RomiDEPsin / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may increase the serum concentration of RomiDEPsin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of rifampin with romidepsin.</p> \n<p><b>Discussion</b> In a clinical study summarized in romidepsin U.S. prescribing information, coadministration with rifampin increased the romidepsin (14 mg/m2 infused over 4 hours) maximum concentration and AUC by 60% and 80%, respectively, in patients with advanced cancer.<sup>1</sup> The mechanism of this interaction is not clear. Rifampin induction of CYP3A4 mediated romidepsin metabolism would normally be expected to decrease rather than increase romidepsin exposure. The manufacturer of romidepsin speculates that the opposite may have been seen in the above study due to rifampin inhibition of hepatic uptake of romidepsin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Istodax (romidepsin). Summit, NJ: Celgene Corporation, June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7655":"<p><b>Title</b> Astemizole / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may enhance the QTc-prolonging effect of Astemizole. Ketoconazole (Systemic) may increase the serum concentration of Astemizole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ketoconazole with astemizole. Ketoconazole U.S. prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Ketoconazole U.S. prescribing information lists coadministration with astemizole as contraindicated due to the potential for ketoconazole to increase astemizole systemic exposure (via inhibition of its metabolism, e.g. via CYP3A4, 2J2)<sup>1,2</sup> and potentiate its QTc prolonging effects.<sup>3</sup> This drug pair has been associated with development of torsades de pointes in two published case reports.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Matsumoto S and Yamazoe Y, “Involvement of Multiple Human Cytochromes P450 in the Liver Microsomal Metabolism of Astemizole and a Comparison With Terfenadine,” <i>Br J Clin Pharmacol</i>, 2001, 51(2):133-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11259984\">[PubMed 11259984]</a></p>\n<p>2. Matsumoto S, Hirama T, Kim HJ, et al, “In Vitro Inhibition of Human Small Intestinal and Liver Microsomal Astemizole O-Demethylation: Different Contribution of CYP2J2 in the Small Intestine and Liver,” <i>Xenobiotica</i>, 2003, 33(6):615-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12851038\">[PubMed 12851038]</a></p>\n<p>3. Prescribing information. Ketoconazole. Morgantown, WV: Mylan Pharmaceuticals Inc., January 2012.</p>\n<p>4. Tsai WC, Tsai LM and Chen JH, “Combined Use of Astemizole and Ketoconazole Resulting in Torsade de Pointes,” <i>J Formos Med Assoc</i>, 1997, 96(2):144-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9071844\">[PubMed 9071844]</a></p>\n<p>5. Kulkarni SM, Agarwal HK and Shaikh AA, “Torsade de Pointes Complicating Treatment With Astemizol,” <i>Indian Heart J</i>, 1994, 46(3):179-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7821942\">[PubMed 7821942]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7656":"<p><b>Title</b> Terfenadine / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may enhance the QTc-prolonging effect of Terfenadine. Ketoconazole (Systemic) may increase the serum concentration of Terfenadine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of ketoconazole with terfenadine. Ketoconazole U.S. prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Ketoconazole U.S. prescribing information lists coadministration with terfenadine as contraindicated due to the potential for ketoconazole to increase terfenadine systemic exposure (primarily via inhibition of its CYP3A mediated metabolism and/or its P-glycoprotein mediated efflux)<sup>1,2,3,4,5,6</sup> and potentiate its QTc prolonging effects.<sup>7</sup><br><br>In a clinical study of 6 healthy volunteers, coadministration of ketoconazole (200 mg twice daily for 7 days) increased the maximum concentration of the acid metabolite of terfenadine (60 mg twice daily) by 57%.<sup>8</sup> One subject had detectable serum concentrations terfenadine while receiving the drug alone, compared to all 6 during ketoconazole coadministraiton. Only 2 subjects completed all 7 days of ketoconazole coadministration; the other 4 experienced pre-dose QTc prolongation in excess of the study protocol’s safety limit (&gt;25% increase from baseline) and completed pharmacokinetic sampling after 4 or 5 days of ketoconazole. The average pre-dose QTc interval was 408 msec prior to any study medication, 416 msec during terfenadine alone, and 490 msec during concomitant terfenadine and ketoconazole. The potential for ketoconazole to increase terfenadine concentrations is also supported by a study conducted by the former terfenadine U.S. manufacturer, reported in brief in a published comment.<sup>9</sup><br><br>In addition to the above clinical studies, two published case reports describe patients who experienced torsades de pointes during coadministration of these drugs.<sup>10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. von Moltke LL, Greenblatt DJ, Duan SX, et al, “In Vitro Prediction of the Terfenadine-Ketoconazole Pharmacokinetic Interaction,” <i>J Clin Pharmacol</i>, 1994, 34(12):1222-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7738219\">[PubMed 7738219]</a></p>\n<p>2. Rodrigues AD, Mulford DJ, Lee RD, et al, “In Vitro Metabolism of Terfenadine by a Purified Recombinant Fusion Protein Containing Cytochrome P4503A4 and NADPH-P450 Reductase. Comparison to Human Liver Microsomes and Precision-Cut Liver Tissue Slices,” <i>Drug Metab Dispos</i>, 1995, 23(7):765-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7587966\">[PubMed 7587966]</a></p>\n<p>3. Ling KH, Leeson GA, Burmaster SD, et al, “Metabolism of Terfenadine Associated With CYP3A(4) Activity in Human Hepatic Microsomes,” <i>Drug Metab Dispos</i>, 1995, 23(6):631-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7587944\">[PubMed 7587944]</a></p>\n<p>4. Jurima-Romet M, Crawford K, Cyr T, et al, “Terfenadine Metabolism in Human Liver. In Vitro Inhibition by Macrolide Antibiotics and Azole Antifungals,” <i>Drug Metab Dispos</i>, 1994, 22(6):849-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7895601\">[PubMed 7895601]</a></p>\n<p>5. Raeissi SD, Hidalgo IJ, Segura-Aguilar J, et al, “Interplay Between CYP3A-Mediated Metabolism and Polarized Efflux of Terfenadine and its Metabolites in Intestinal Epithelial Caco-2 (TC7) Cell Monolayers,” <i>Pharm Res</i>, 1999, 16(5):625-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10350002\">[PubMed 10350002]</a></p>\n<p>6. Kim RB, Wandel C, Leake B, et al, “Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein,” <i>Pharm Res</i>, 1999, 16(3):408-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10213372\">[PubMed 10213372]</a></p>\n<p>7. Prescribing information. Ketoconazole. Morgantown, WV: Mylan Pharmaceuticals Inc., January 2012.</p>\n<p>8. Honig PK, Wortham DC, Zamani K, et al, “Terfenadine-Ketoconazole Interaction. Pharmacokinetic and Electrocardiographic Consequences,” <i>JAMA</i>, 1993, 269(12):1513-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8445813\">[PubMed 8445813]</a></p>\n<p>9. Mathews DR, McNutt B, Okerholm R, et al, “Torsades de Pointes Occurring in Association With Terfenadine Use,” <i>JAMA</i>, 1991, 266(17):2375-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1920744\">[PubMed 1920744]</a></p>\n<p>10. Zimmermann M, Duruz H, Guinand O, et al, “Torsades de Pointes After Treatment With Terfenadine and Ketoconazole,” <i>Eur Heart J</i>, 1992, 13(7):1002-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1644069\">[PubMed 1644069]</a></p>\n<p>11. Monahan BP, Ferguson CL, Killeavy ES, et al, “Torsades de Pointes Occurring in Association With Terfenadine Use,” <i>JAMA</i>, 1990, 264(21):2788-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1977935\">[PubMed 1977935]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7658":"<p><b>Title</b> MitoXANTRONE / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of MitoXANTRONE. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider mitoxantrone dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution and monitor closely for toxic effects of mitoxantrone.</p> \n<p><b>Discussion</b> Cyclosporine U.S. prescribing information warns that higher cyclosporine doses (e.g., those greater than 16 mg/kg/day) may increase exposure to mitoxantrone.<sup>1,2</sup> In a clinical study of 38 children with acute myeloid leukemia, coadministration of cyclosporine (continuous infusion, dosed to achieve plasma concentration 3-5 mcg/mL) during treatment with mitoxantrone, etoposide, and intrathecal cytarabine decreased mitoxantrone clearance by 42%.<sup>3</sup> The mitoxantrone dose was empirically reduced by 40% with concomitant cyclosporine, resulting in a 12% higher mitoxantrone AUC with cyclosporine than without. <br><br>Cyclosporine has been added to drug regimens containing mitoxantrone in several other clinical investigations, with or without empiric mitoxantrone dose adjustment.<sup>4,5,6,7,8,9</sup> However, the small numbers of patients studied and the wide variability in study characteristics (e.g., patient population, drug regimen, control conditions) preclude any confident generalization about the overall impact of cyclosporine on mitoxantrone efficacy and toxicity from these data.<br><br>The exact mechanism of interaction between these agents is not clear. Cyclosporine inhibition of transporters mediating mitoxantrone transport (e.g., BCRP) could theoretically contribute. Similarly, cyclosporine could theoretically have the beneficial effect of inhibiting some forms of transporter-related mitoxantrone resistance.<sup>10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sandimmune (cyclosporine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, May 2013.</p>\n<p>2. Prescribing information. Neoral (cyclosporine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, May 2013.</p>\n<p>3. Lacayo NJ, Lum BL, Becton DL, et al, “Pharmacokinetic Interactions of Cyclosporine With Etoposide and Mitoxantrone in Children With Acute Myeloid Leukemia,” <i>Leukemia</i>, 2002, 16(5):920-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11986955\">[PubMed 11986955]</a></p>\n<p>4. Daenen S, van der Holt B, Verhoef GE, et al, “Addition of Cyclosporin A to the Combination of Mitoxantrone and Etoposide to Overcome Resistance to Chemotherapy in Refractory or Relapsing Acute Myeloid Leukaemia: A Randomised Phase II Trial From HOVON, the Dutch-Belgian Haemato-Oncology Working Group for Adults,” <i>Leuk Res</i>, 2004, 28(10):1057-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15289018\">[PubMed 15289018]</a></p>\n<p>5. Dahl GV, Lacayo NJ, Brophy N, et al, “Mitoxantrone, Etoposide, and Cyclosporine Therapy in Pediatric Patients With Recurrent or Refractory Acute Myeloid Leukemia,” <i>J Clin Oncol</i>, 2000, 18(9):1867-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10784627\">[PubMed 10784627]</a></p>\n<p>6. Tallman MS, Lee S, Sikic BI, et al, “Mitoxantrone, Etoposide, and Cytarabine Plus Cyclosporine for Patients With Relapsed or Refractory Acute Myeloid Leukemia: An Eastern Cooperative Oncology Group Pilot Study,” <i>Cancer</i>, 1999, 85(2):358-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10023703\">[PubMed 10023703]</a></p>\n<p>7. Chen TL, Estey EH, Othus M, et al, “Cyclosporine Modulation of Multidrug Resistance in Combination With Pravastatin, Mitoxantrone and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1/2 Study,” <i>Leuk Lymphoma</i>, 2013, Mar 27. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23432687\">[PubMed 23432687]</a></p>\n<p>8. Stiff PJ, Bayer R, Tan S, et al, “High-Dose Chemotherapy Combined With Escalating Doses of Cyclosporin A and an Autologous Bone Marrow Transplant for the Treatment of Drug-Resistant Solid Tumors: A Phase I Clinical Trial,” <i>Clin Cancer Res</i>, 1995, 1(12):1495-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9815949\">[PubMed 9815949]</a></p>\n<p>9. Marie JP, Bastie JN, Coloma F, et al, “Cyclosporin A as a Modifier Agent in the Salvage Treatment of Acute Leukemia (AL),” <i>Leukemia</i>, 1993, 7(6):821-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8099134\">[PubMed 8099134]</a></p>\n<p>10. Gupta A, Dai Y, Vethanayagam RR, et al, “Cyclosporin A, Tacrolimus and Sirolimus are Potent Inhibitors of the Human Breast Cancer Resistance Protein (ABCG2) and Reverse Resistance to Mitoxantrone and Topotecan,” <i>Cancer Chemother Pharmacol</i>, 2006, 58(3):374-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16404634\">[PubMed 16404634]</a></p>\n<p>11. Garcia-Escarp M, Martinez-Munoz V, Sales-Pardo I, et al, “Flow Cytometry-Based Approach to ABCG2 Function Suggests That the Transporter Differentially Handles the Influx and Efflux of Drugs,” <i>Cytometry A</i>, 2004, 62(2):129-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15517563\">[PubMed 15517563]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7659":"<p><b>Title</b> Propofol / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may enhance the hypotensive effect of Propofol. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Note that use of propofol in a patient who has been taking rifampin may result in clinically significant hypotension. If possible, avoid use of this combination.</p> \n<p><b>Discussion</b> The mean arterial pressure (MAP) declined significantly more among patients exposed to rifampin plus propofol (-38 mmHg) as compared to patients exposed to either propofol alone (-22 mmHg) or rifampin plus thiopental (-16 mmHg) in a retrospective study of patients who received rifampin premedication (600 mg the night before and 600 mg approximately 2 hours prior to surgery) with subsequent propofol anesthesia (n=25), patients receiving propofol anesthesia but without rifampin premedication (n=25), and patients who received rifampin premedication with thiopental anesthesia (n=25).<sup>1</sup> Patients were also matched on several variables, and analyses further adjusted for demographic differences among the groups. In addition to these differences in MAP among the groups, patients exposed to rifampin plus propofol also had a significantly longer average duration of hypotension (33 minutes vs. 9-13 minutes), greater vasopressor use, and increased intraoperative fluid requirements.<sup>1</sup> A published case also details a significant occurrence of this purported interaction in a 64-year-old woman who received rifampin prior to spinal surgery for a herniated disk and then propofol for anesthesia along with succinylcholine.<sup>1</sup> Shortly after induction of anesthesia the patient experienced a sustained period of hypotension that required vigorous treatment with fluids and vasopressors.<br><br>The primary mechanism of this interaction is largely unknown, though additive or synergistic vasodilating effects mediated by nitric oxide has been proposed as the primary underlying mechanism.<sup>1</sup> Propofol appears to relax smooth muscle tone by increasing the production and release of nitric oxide.<sup>1,2,3</sup> Also, rifampin has been shown to upregulate the transcription of NO synthase in vitro in both human alveolar and liver epithelial cells.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mirzakhani H, Rosow C, Wang J, et al, “Profound Hypotension after Anesthetic Induction with Propofol in Patients Treated with Rifampin,” <i>Anesth Analg</i>, 2013, <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23687230\">[PubMed 23687230]</a></p>\n<p>2. Park KW, Dai HB, Lowenstein E, et al, “Propofol-Associated Dilation of Rat Distal Coronary Arteries is Mediated by Multiple Substances, Including Endothelium-Derived Nitric Oxide,” <i>Anesth Analg</i>, 1995, 81(6):1191-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7486103\">[PubMed 7486103]</a></p>\n<p>3. Petros AJ, Bogle RG, Pearson JD, “Propofol Stimulates Nitric Oxide Release from Cultured Porcine Aortic Endothelial Cells,” <i>Br J Pharmacol</i>, 1993, 109:6-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8388302\">[PubMed 8388302]</a> </p>\n<p>4. Yuhas Y, Berent E, Ashkenazi S, et al, “Rifampin Augments Cytokine-Induced Nitric Oxide Production in Human Alveolar Epithelial Cells,” <i>Antimicrob Agents Chemother</i>, 2006, 50:396-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16377722\">[PubMed 16377722]</a></p>\n<p>5. Yuhas Y, Berent E, Ashkenazi S, “Effect of Rifampin on Production of Inflammatory Mediators in HepG2 Liver Epithelial Cells,” <i>Antimicrob Agents Chemother</i>, 2011, 55(12):5541-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21930886\">[PubMed 21930886]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7660":"<p><b>Title</b> Rilpivirine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rilpivirine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Increase monitoring for adverse effects of rilpivirine when used together with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The rilpivirine AUC was increased by an average of 1.5- to 2.3-fold when used together with the strong CYP3A4 inhibitors lopinavir/ritonavir, darunavir/ritonavir, ketoconazole, or telaprevir.<sup>1</sup> The rilpivirine prescribing information states that despite these reported increases in rilpivirine concentrations, no dose adjustments are necessary. The lone exception to this, according to the prescribing information are the macrolide antibiotics (i.e., clarithromycin, erythromycin, and telithromycin), for which it is recommended to consider alternatives such as azithromycin when possible.<sup>1</sup><br><br>The likely mechanism for these interactions is inhibition of the CYP3A-mediated metabolism of rilpivirine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Edurant (rilpivirine). Titusville, NJ: Janssen Products, LP, June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7661":"<p><b>Title</b> Rilpivirine / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Macrolide Antibiotics may increase the serum concentration of Rilpivirine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider the use of an alternative antibiotic that is less likely to interact, such as azithromycin or a non-macrolide antibiotic when appropriate. If an interacting combination is necessary, monitor patients extra closely for evidence of rilpivirine toxicity.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Clarithromycin, Erythromycin (Systemic), Telithromycin<br><b>Exceptions</b> Azithromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin</p>\n</div> \n<p><b>Discussion</b> The rilpivirine AUC was increased by an average of 1.5- to 2.3-fold when used together with the strong CYP3A4 inhibitors lopinavir/ritonavir, darunavir/ritonavir, ketoconazole, or telaprevir.<sup>1</sup> The rilpivirine prescribing information states that despite these reported increases in rilpivirine concentrations, no dose adjustments are necessary. The lone exception to this, according to the prescribing information are the macrolide antibiotics (i.e., clarithromycin, erythromycin, and telithromycin), for which it is recommended to consider alternatives such as azithromycin when possible.<sup>1</sup><br><br>The likely mechanism for these interactions is inhibition of the CYP3A-mediated metabolism of rilpivirine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Edurant (rilpivirine). Titusville, NJ: Janssen Products, LP, June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7662":"<p><b>Title</b> Quinagolide / Amisulpride</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The strength of this warning varies according to the country in which the amisulpride product was approved and marketed.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amisulpride may diminish the therapeutic effect of Quinagolide. Quinagolide may diminish the therapeutic effect of Amisulpride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of amisulpride and quinagolide. Some, but not all, amisulpride brands specifically state that this combination must not be used.</p> \n<p><b>Discussion</b> According to the summary of product characteristics for at least some amisulpride brands, combination with the dopamine agonists cabergoline or quinagolide must not be used;<sup>1</sup> however, not all labels specifically mention avoidance of the combination.<sup>2</sup><br><br>The concern with the combination is that cabergoline or quinagolide (dopamine receptor agonists) and amisulpride (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Solian (amisulpride). Quetigny, France: Sanofi Winthrop Industrie, 06/2009.</p>\n<p>2. Summary of product characteristics. Solian (amisulpride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7663":"<p><b>Title</b> Cabergoline / Amisulpride</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The strength of this warning varies according to the country in which the amisulpride product was approved and marketed.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amisulpride may diminish the therapeutic effect of Cabergoline. Cabergoline may diminish the therapeutic effect of Amisulpride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of amisulpride and cabergoline. Some, but not all, amisulpride brands specifically state that this combination must not be used.</p> \n<p><b>Discussion</b> According to the summary of product characteristics for at least some amisulpride brands, combination with the dopamine agonists cabergoline or quinagolide must not be used;<sup>1</sup> however, not all labels specifically mention avoidance of the combination.<sup>2</sup><br><br>The concern with the combination is that cabergoline or quinagolide (dopamine receptor agonists) and amisulpride (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Solian (amisulpride). Quetigny, France: Sanofi Winthrop Industrie, 06/2009.</p>\n<p>2. Summary of product characteristics. Solian (amisulpride). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 01/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7664":"<p><b>Title</b> Amphetamines / Ascorbic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ascorbic Acid may decrease the serum concentration of Amphetamines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to amphetamines when used together with ascorbic acid as reduced absorption of amphetamines may result, possibly leading to decreased concentration and diminished clinical response.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> Concurrent use of amphetamines with ascorbic acid is expected to decrease the absorption of amphetamines from the GI tract, leading to reduced serum amphetamine concentrations and possibly to reduced efficacy.<sup>1,2</sup><br><br>The prescribing information for some amphetamine products also suggests that ascorbic acid may acidify the urine, resulting in increased urinary excretion of the amphetamine and reduced serum concentrations.<sup>3</sup> Despite this claim, many studies have concluded that ascorbic acid (at doses from 1-2 g administered as single doses or up to four times per day, and including oral or IV) has no significant impact on urinary pH.<sup>4,5,6,7,8,9,10,11</sup> It has also been proposed that the potentially relevant change in urine pH with ascorbic acid reported in a few studies of patients with a UTI<sup>12,13,14,15</sup> is likely the result of inhibition of bacterial urease, making the results more a reflection of decreased alkalinization than any true acidification.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Adderall (dextroamphetamine and amphetamine). Wayne, PA: Shire US Inc., 3/07.</p>\n<p>2. Prescribing information. Dexedrine (dextroamphetamine). Research Triangle Park, NC: GlaxoSmithKline, July 2008.</p>\n<p>3. Prescribing information. Vyvanse (lisdexamfetamine). Wayne, PA: Shire US Inc., June 2013.</p>\n<p>4. Traxer O, Huet B, Poindexter J, et al, “Effect of Ascorbic Acid Consumption on Urinary Stone Risk Factors,” <i>J Urol</i>, 2003, 170(2 Pt 1):397-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12853784\">[PubMed 12853784]</a></p>\n<p>5. Baxmann AC, De O G Mendonca C, et al, “Effect of Vitamin C Supplements on Urinary Oxalate and pH in Calcium Stone-Forming Patients,” <i>Kidney Int</i>, 2003, 63(3):1066-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12631089\">[PubMed 12631089]</a></p>\n<p>6. Strom JG Jr, Jun HW, “Effect of Urine pH and Ascorbic Acid on the Rate of Conversion of Methenamine to Formaldehyde,” <i>Biopharm Drug Dispos</i>, 1993, 14(1):61-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8427945\">[PubMed 8427945]</a></p>\n<p>7. Wall I, Tiselius HG, “Long-Term Acidification of Urine in Patients Treated for Infected Renal Stones,” <i>Urol Int</i>, 1990, 45(6):336-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2288050\">[PubMed 2288050]</a></p>\n<p>8. Axelrod DR. “Ascorbic Acid and Urinary pH,” <i>JAMA</i>, 1985, 254(10):1310-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4021006\">[PubMed 4021006]</a></p>\n<p>9. Trang JM, Blanchard J, Conrad KA, et al, “Effect of Dietary Ascorbic Acid Restriction and Supplementation on Urine pH in Elderly Males,” <i>JAMA</i>, 1984, 252(21):2960-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6502855\">[PubMed 6502855]</a></p>\n<p>10. Barton CH, Sterling ML, Thomas R, et al, “Ineffectiveness of Intravenous Ascorbic Acid as an Acidifying Agent in Man,” <i>Arch Intern Med</i>, 1981, 141(2):211-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7458517\">[PubMed 7458517]</a></p>\n<p>11. Naccarto DV, Bell CJ, Lamy PP, “Appraisal of Ascorbic Acid for Acidifying the Urine of Methenamine-Treated Geriatric Patients,” <i>J Am Geriatr Soc</i>, 1979, 27(1):34-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32196\">[PubMed 32196]</a></p>\n<p>12. Nahata MC, Cummins BA, McLeod DC, “Effect of Ascorbic Acid on Urine pH,” <i>Am J Hosp Pharm</i>, 1981, 38(1):33, 36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7211868\">[PubMed 7211868]</a></p>\n<p>13. Hetey SK, Kleinberg ML, Parker WD, et al, “Effect of Ascorbic Acid on Urine pH in Patients with Injured Spinal Cords,” <i>Am J Hosp Pharm</i>, 1980, 37(2):235-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7361797\">[PubMed 7361797]</a></p>\n<p>14. Nahata MC, Shrimp L, Lampman T, et al, “Effect of Ascorbic Acid on Urine pH in Man,” <i>Am J Hosp Pharm</i>, 1977, 34(11):1234-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22245\">[PubMed 22245]</a></p>\n<p>15. Houston JB, Levy G, “Modification of Drug Biotransformation by Vitamin C in Man,” <i>Nature</i>, 1975, 255(5503):78-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1128674\">[PubMed 1128674]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7665":"<p><b>Title</b> Amphetamines / Urinary Acidifying Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Urinary Acidifying Agents may decrease the serum concentration of Amphetamines. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor response to amphetamines when used together with urinary acidifying agents as increased excretion of amphetamines may result, possibly leading to decreased concentration and diminished clinical response.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n <p><b>Urinary Acidifying Agents Interacting Members</b> Ammonium Chloride, Methenamine, Piperazine, Potassium Phosphate, Sodium Acid Phosphate</p>\n</div> \n<p><b>Discussion</b> The pH-dependent renal excretion of amphetamines has been repeatedly demonstrated. Acidification of the urine (with ammonium chloride, dosed to pH = 5.3) was shown in one study to increase renal excretion of (+)-amphetamine to 59.0-83.5% of a dose within 24 hours from an average of 32.9% (12-44%) with unregulated urinary pH.<sup>1</sup> In another study, acidification of the urine resulted in more than a 3-fold increase in mean 16-hour excretion of amphetamine compared to that excreted in 16 hours with uncontrolled urinary pH (mean 54.5% vs. 14.5%, respectively; n=6).<sup>2</sup> Acidification of the urine has also been shown to reduce amphetamine plasma concentrations,<sup>3</sup> shorten the elimination half-life,<sup>4</sup> and increase urinary excretion rate.<sup>3</sup><br><br>Studies with amphetamine derivatives (e.g., ephedrine, methylamphetamine, etc.) have generally shown this same pH-dependent renal excretion of unchanged drug,<sup>5</sup> with observations that increasing methylation of the amino group increases this pH-dependence.<sup>5</sup><br><br>The ability to hasten amphetamine removal via acidification has also generated interest in using this to treat cases of amphetamine overdose or toxicity, with studies demonstrating the utility of strategy for both amphetamine<sup>6</sup> and methamphetamine<sup>7</sup> overdoses.<br><br>The most simple mechanism of this interaction that has been proposed is that the basic amphetamine molecule becomes ionized in the acidic filtrate, preventing any renal tubular reabsorption and enhancing urinary elimination. An alternative mechanism has also been proposed after a pharmacokinetic study demonstrated that preventing tubular reabsorption alone would not be able to account for the substantial impact of acidification on plasma amphetamine concentrations and urinary excretion rates.<sup>3</sup> Under this proposed alternative mechanism, diffusion of parent drug directly into the filtrate occurs as a result of the tremendous concentration gradient for unchanged drug between plasma and filtrate (where virtually all amphetamine present is in its ionized form), resulting in enhanced elimination (beyond simply filtered drug becoming ionized and trapped in filtrate/urine) and reduced plasma concentrations.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beckett AH, Rowland M, “Urinary Excretion Kinetics of Amphetamine in Man,” <i>J Pharm Pharmacol</i>, 1965, 17(10):628-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4379686\">[PubMed 4379686]</a></p>\n<p>2. Beckett AH, Rowland M, Turner P, “Influence of Urinary pH on Excretion of Amphetamine,” <i>Lancet</i>, 1965, 1:303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14247879\">[PubMed 14247879]</a></p>\n<p>3. Beckett AH, Salmon JA, Mitchard M, “The Relation Between Blood Levels and Urinary Excretion of Amphetamine Under Controlled Acidic and Under Fluctuating Urinary pH Values Using [14C] Amphetamine,” <i>J Pharm Pharmacol</i>, 1969, 21(4):251-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4390145\">[PubMed 4390145]</a></p>\n<p>4. Davis JM, Kopin IJ, Lemberger L, et al, “Effects of Urinary pH on Amphetamine Metabolism,” <i>Ann NY Acad Sci</i>, 1971, 179:493-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5285389\">[PubMed 5285389]</a></p>\n<p>5. Wilkinson GR, Beckett AH, “Absorption Metabolism and Excretion of the Ephedrines in Man. I. The Influence of Urinary pH and Urine Volume Output,” <i>J Pharmacol Exp Ther</i>, 1968, 162(1):139-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5656593\">[PubMed 5656593]</a></p>\n<p>6. Anggard E, Jonsson LE, Hogmark AL, et al, “Amphetamine Metabolism in Amphetamine Psychosis,” <i>Clin Pharmacol Ther</i>, 1973, 14(5):870-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4729903\">[PubMed 4729903]</a></p>\n<p>7. Gary NE, Saidi P, “Methamphetamine Intoxication. A Speedy New Treatment,” <i>Am J Med</i>, 1978, 64(3):537-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=637062\">[PubMed 637062]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7666":"<p><b>Title</b> Simvastatin / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of clarithromycin with simvastatin is contraindicated. Due to a possible risk of simvastatin-associated toxicities (including rhabdomyolysis), if clarithromycin is needed, simvastatin should be suspended during the course of treatment.</p> \n<p><b>Discussion</b> Concurrent use of clarithromycin or erythromycin together with simvastatin, lovastatin, or atorvastatin was associated with an increased risk of hospitalization for rhabdomyolysis (RR=2.2), acute kidney injury (RR=1.8), or all-cause mortality (RR=1.6), as compared to concurrent use of azithromycin with the statins, in a cohort study of 75,858 patients on clarithromycin or erythromycin, and 68,478 patients on azithromycin.<sup>1</sup> Similarly, several case reports describe rhabdomyolysis associated with simvastatin when used in combination with clarithromycin, mostly involving higher-dose simvastatin (i.e., 40 mg or 80 mg daily) and higher clarithromycin doses (i.e., 500 mg twice/day).<sup>2,3,4,5,6,7,8</sup> The AUC of simvastatin and its active metabolite, simvastatin acid, were an average of 10-fold and 12-fold higher, respectively, with concurrent clarithromycin.<sup>9</sup><br><br>The degree to which azithromycin, largely considered a safer alternative with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>1</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>10,11</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>12</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>13</sup><br><br>Several mechanisms likely contribute to these observed interactions. One mechanism appears to be clarithromycin inhibition of the CYP3A4-mediated metabolism of simvastatin. However, considering that the disposition of simvastatin appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1),<sup>14,15,16</sup> and that clarithromycin may inhibit SLCO1B1 activity, this inhibition of hepatic uptake may also contribute to this interaction to some degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. <i>Ann Intern Med</i>. 2013;158(12):869-876. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>2. Page SR, Yee KC. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. <i>Intern Med J</i>. 2014;44(7):690-693. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25041770\">[PubMed 25041770]</a></p>\n<p>3. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. <i>Pharmacotherapy</i>. 2007;27(4):603-607. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17381388\">[PubMed 17381388]</a></p>\n<p>4. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. <i>Ann Pharmacother</i>. 2005;39(10):1760-1761. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16159992\">[PubMed 16159992]</a></p>\n<p>5. Trieu J, Emmett L, Perera C, Thanakrishnan K, Van Der Wall H. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy. <i>Clin Nucl Med</i>. 2004;29(12):803-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15545884\">[PubMed 15545884]</a></p>\n<p>6. Kahri AJ, Valkonen MM, Vuoristo MK, Pentikainen PJ. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. <i>Ann Pharmacother</i>. 2004;38(4):719. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14966253\">[PubMed 14966253]</a></p>\n<p>7. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. <i>Ann Pharmacother</i>. 2001;35(1):26-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197581\">[PubMed 11197581]</a></p>\n<p>8. Wagner J, Suessmair C, Pfister HW. Rhabdomyolysis caused by co-medication with simvastatin and clarithromycin. <i>J Neurol</i>. 2009;256(7):1182-1183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19252767\">[PubMed 19252767]</a></p>\n<p>9. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. <i>Am J Cardiol</i>. 2004;94(9):1140-1146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15518608\">[PubMed 15518608]</a></p>\n<p>10. Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. <i>Ann Pharmacother</i>. 1997;31(7-8):859-863. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>11. Alreja G, Inayatullah S, Goel S, Braden G. Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin. <i>J Cardiovasc Dis Res</i>. 2012;3(4):319-322. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>12. Strandell J, Bate A, Hagg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. <i>Br J Clin Pharmacol</i>. 2009;68(3):427-434. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>13. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. <i>J Clin Pharmacol</i>. 2002;42(4):444-449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>14. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. <i>Drug Metab Dispos</i>. 2007;35(5):779-786. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>15. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy--a genomewide study. <i>N Engl J Med</i>. 2008;359(8):789-799. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>16. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. <i>Pharmacogenet Genomics</i>. 2006;16(12):873-879. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7667":"<p><b>Title</b> Lovastatin / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Lovastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of clarithromycin with lovastatin is contraindicated. Due to a possible risk of lovastatin-associated toxicities (including rhabdomyolysis), if clarithromycin is needed, lovastatin should be suspended during the course of treatment.</p> \n<p><b>Discussion</b> Concurrent use of clarithromycin or erythromycin together with simvastatin, lovastatin, or atorvastatin was associated with an increased risk of hospitalization for rhabdomyolysis (RR=2.2), acute kidney injury (RR=1.8), or all-cause mortality (RR=1.6), as compared to concurrent use of azithromycin with the statins, in a cohort study of 75,858 patients on clarithromycin or erythromycin, and 68,478 patients on azithromycin.<sup>1</sup> Similarly, case reports describe rhabdomyolysis associated with simvastatin when used in combination with clarithromycin.<sup>2,3</sup><br><br>The degree to which azithromycin, largely considered a safer alternative with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>1</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>4,5</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>6</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>7</sup><br><br>Several mechanisms likely contribute to these observed interactions. One mechanism appears to be clarithromycin inhibition of the CYP3A4-mediated metabolism of lovastatin. However, considering that the disposition of many statins appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1),<sup>8,9,10</sup> and that clarithromycin may inhibit SLCO1B1 activity, this inhibition of hepatic uptake may also contribute to this interaction to some degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Patel AM, Shariff S, Bailey DG, et al, “Statin Toxicity from Macrolide Antibiotic Coprescription: A Population-Based Cohort Study,” <i>Ann Intern Med</i>, 2013, 158:869-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>2. Ayanian JZ, Fuchs CS, and Stone RM, “Lovastatin and Rhabdomyolysis,” <i>Ann Intern Med</i>, 1988, 109(8):682-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3421582\">[PubMed 3421582]</a></p>\n<p>3. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>4. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>5. Alreja G, Inayatullah S, Goel S, et al, “Rhabdomyolysis Caused by an Unusual Interaction between Azithromycin and Simvastatin,” <i>J Cardiovasc Dis Res</i>, 2012, 3(4):319-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>6. Strandell J, Bate A, Hagg S, et al, “Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction,” <i>Br J Clin Pharmacol</i>, 2009, 68(3):427-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>7. Amsden GW, Kuye O, and Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin With Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(4):444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>8. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>9. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>10. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7668":"<p><b>Title</b> AtorvaSTATin / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit atorvastatin to a maximum dose of 20 mg/day when used with clarithromycin. If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> Concurrent use of clarithromycin or erythromycin together with simvastatin, lovastatin, or atorvastatin was associated with an increased risk of hospitalization for rhabdomyolysis (RR=2.2), acute kidney injury (RR=1.8), or all-cause mortality (RR=1.6), as compared to concurrent use of azithromycin with the statins, in a cohort study of 75,858 patients on clarithromycin or erythromycin, and 68,478 patients on azithromycin.<sup>1</sup> Similarly, case reports describe rhabdomyolysis associated with atorvastatin when used in combination with clarithromycin.<sup>2,3</sup> The AUC of atorvastatin was increased by an average of 83% to 4.4-fold with concurrent clarithromycin.<sup>4,5</sup><br><br>The degree to which azithromycin, largely considered a safer alternative with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>1</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>6,7</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>8</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>4</sup><br><br>Several mechanisms likely contribute to these observed interactions. One mechanism appears to be clarithromycin inhibition of the CYP3A4-mediated metabolism of atorvastatin. However, considering that the disposition of many statins appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1),<sup>9,10,11</sup> and that clarithromycin may inhibit SLCO1B1 activity, this inhibition of hepatic uptake may also contribute to this interaction to some degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Patel AM, Shariff S, Bailey DG, et al, “Statin Toxicity from Macrolide Antibiotic Coprescription: A Population-Based Cohort Study,” <i>Ann Intern Med</i>, 2013, 158:869-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>2. Mah Ming JB, Gill MJ, “Drug-Induced Rhabdomyolysis after Concomitant Use of Clarithromycin, Atorvastatin, and Lopinavir/Ritonavir in a Patient with HIV,” <i>AIDS Patient Care STDS</i>, 2003, 17(5):207-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12816614\">[PubMed 12816614]</a></p>\n<p>3. Sipe BE, Jones RJ, and Bokhart GH, “Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction,” <i>Ann Pharmacother</i>, 2003, 37(6):808-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12773066\">[PubMed 12773066]</a></p>\n<p>4. Amsden GW, Kuye O, and Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(4):444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>5. Prescribing information. Lipitor (atorvastatin). New York, NY: Pfizer Inc, 10/2012.</p>\n<p>6. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>7. Alreja G, Inayatullah S, Goel S, et al, “Rhabdomyolysis Caused by an Unusual Interaction between Azithromycin and Simvastatin,” <i>J Cardiovasc Dis Res</i>, 2012, 3(4):319-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>8. Strandell J, Bate A, Hagg S, et al, “Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction,” <i>Br J Clin Pharmacol</i>, 2009, 68(3):427-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>9. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>10. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>11. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7669":"<p><b>Title</b> Pravastatin / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Pravastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Limit pravastatin to a maximum of 40 mg/day when used in combination with clarithromycin. If this combination is used, monitor patients more closely for evidence of pravastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> The pravastatin AUC was an average of 110% higher with concurrent use of clarithromycin (500 mg twice/day x 9 days), resulting in a recommendation in the pravastatin prescribing information that the pravastatin dose be limited to a maximum of 40 mg/day when used with clarithromycin.<sup>1</sup> Patients taking a non-CYP3A4-metabolized statin, such as pravastatin (approximately 21% of patients), with clarithromycin had a modest but statistically significant increase in the risk of hospital admission with hyperkalemia or acute kidney injury, and all-cause mortality compared to patients taking azithromycin (not a substantial inhibitor of OATP1B1) in a population based, retrospective cohort study of 104,041 patients aged 66 years and older.<sup>2</sup> There was a similarly modest, but non-statistically-significant increase in risk for hospitalization for rhabdomyolysis with clarithromycin vs. azithromycin. The absolute risk increase was quite small (0.02% to 0.11%) for these outcomes, largely due to the small numbers of events in both groups, resulting in estimates that more than 900 to 5000 patients would have to be exposed to this combination to result in one of these outcomes.<br><br>Pravastatin is generally considered to be subject to a lower risk of having a significant interaction with the CYP3A4-inhibiting macrolide antibiotics (erythromycin, clarithromycin, telithromycin) due to its lack of appreciable CYP3A4 metabolism.<sup>1</sup> The most likely mechanism for any pravastatin-macrolide interaction is inhibition of the SLCO1B1 uptake transporter leading to reduced hepatic uptake of pravastatin. The disposition of many statins, including pravastatin, appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1), and clarithromycin and other macrolides may inhibit SLCO1B1 activity.<sup>3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Pravachol</i> (pravastatin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2012.</p>\n<p>2. Li DQ, Kim R, Mcarthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. <i>CMAJ</i>. 2014; Dec 22 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25534598\">[PubMed 25534598]</a></p>\n<p>3. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. <i>Drug Metab Dispos</i>. 2007;35(5):779-786. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>4. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy--a genomewide study. <i>N Engl J Med</i>. 2008;359(8):789-979. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>5. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. <i>Pharmacogenet Genomics</i>. 2006;16(12):873-879. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p>6. Igel M, Arnold KA, Niemi M, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. <i>Clin Pharmacol Ther</i>. 2006;79(5):419-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16678544\">[PubMed 16678544]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7670":"<p><b>Title</b> Pitavastatin / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Pitavastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use extra caution when considering the use of clarithromycin in a patient being treated with pitavastatin. If this combination is used, monitor patients more closely for evidence of pitavastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> Pitavastatin is generally considered to be subject to a lower risk of having a significant interaction with the CYP3A4-inhibiting macrolide antibiotics (erythromycin, clarithromycin, telithromycin) due to its lack of appreciable CYP3A4 metabolism.<sup>1</sup> Although specific data regarding the combination of pitavastatin and clarithromycin are not available, concurrent use of erythromycin (500 mg four times per day x 6 days) with pitavastatin was associated with an average 2.8-fold increase in pitavastatin AUC,<sup>1</sup> suggesting that a clinically significant interaction between pitavastatin and macrolides may be possible.<br><br>The most likely mechanism for any pitavastatin-macrolide interaction is inhibition of the SLCO1B1 uptake transporter leading to reduced hepatic uptake of pitavastatin. The disposition of many statins, including pitavastatin, appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1), and erythromycin and other macrolides may inhibit SLCO1B1 activity.<sup>2,3,4</sup> Other possible mechanisms for this interaction include alteration of the ABCG2 (BCRP)-mediated transport of pitavastatin,<sup>5,6</sup>, and/or glucuronidation of pitavastatin by UGT1A3 and UGT2B7.<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Livalo (pitavastatin). Montgomery, AL: Kowa Pharmaceuticals America, Inc., 10/2012.</p>\n<p>2. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>3. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>4. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p>5. Ieiri I, Suwannakul S, Maeda K, et al, “SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2007, 82:541-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17460607\">[PubMed 17460607]</a></p>\n<p>6. Hirano M, Maeda K, Matsushima S, et al, “Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin,” <i>Mol Pharmacol</i>, 2005, 68:800-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955871\">[PubMed 15955871]</a></p>\n<p>7. Fujino H, Yamada I, Shimada S, et al, “Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase: Human UDP-Glucuronosyltransferase Enzymes Involved in Lactonization,” <i>Xenobiotica</i>, 2003, 33:27-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12519692\">[PubMed 12519692]</a></p>\n<p>8. Yamada I, Fujino H, Shimada S, et al, “Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase: Similarities and Difference in the Metabolism of Pitavastatin in Monkeys and Humans,” <i>Xenobiotica</i>, 2003, 33:789-803. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12893526\">[PubMed 12893526]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7671":"<p><b>Title</b> AtorvaSTATin / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use extra caution when considering the use of erythromycin in a patient being treated with atorvastatin. Such concurrent use has been associated with significant morbidity and mortality. If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> Concurrent use of clarithromycin or erythromycin together with simvastatin, lovastatin, or atorvastatin was associated with an increased risk of hospitalization for rhabdomyolysis (RR=2.2), acute kidney injury (RR=1.8), or all-cause mortality (RR=1.6), as compared to concurrent use of azithromycin with the statins, in a cohort study of 75,858 patients on clarithromycin or erythromycin, and 68,478 patients on azithromycin.<sup>1</sup> Studies with erythromycin have also reported a 33% average increase in atorvastatin AUC.<sup>2,3</sup><br><br>The degree to which azithromycin, largely considered a safer alternative with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>1</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>4,5</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>6</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>7</sup><br><br>Several mechanisms likely contribute to these observed interactions. One mechanism appears to be erythromycin inhibition of the CYP3A4-mediated metabolism of atorvastatin. However, considering that the disposition of many statins appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1),<sup>8,9,10</sup> and that erythromycin may inhibit SLCO1B1 activity, this inhibition of hepatic uptake may also contribute to this interaction to some degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Patel AM, Shariff S, Bailey DG, et al, “Statin Toxicity from Macrolide Antibiotic Coprescription: A Population-Based Cohort Study,” <i>Ann Intern Med</i>, 2013, 158:869-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>2. Prescribing information. Lipitor (atorvastatin). New York, NY: Pfizer Inc, 10/2012.</p>\n<p>3. Siedlik PH, Olson SC, Yang BB, et al, “Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations,” <i>J Clin Pharmacol</i>, 1999, 39(5):501-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10234598\">[PubMed 10234598]</a></p>\n<p>4. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>5. Alreja G, Inayatullah S, Goel S, et al, “Rhabdomyolysis Caused by an Unusual Interaction between Azithromycin and Simvastatin,” <i>J Cardiovasc Dis Res</i>, 2012, 3(4):319-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>6. Strandell J, Bate A, Hagg S, et al, “Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction,” <i>Br J Clin Pharmacol</i>, 2009, 68(3):427-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>7. Amsden GW, Kuye O, and Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin With Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(4):444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>8. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>9. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>10. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7672":"<p><b>Title</b> Pravastatin / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of Pravastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use extra caution when considering the use of erythromycin in a patient being treated with pravastatin. If this combination is used, monitor patients more closely for evidence of pravastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> Pravastatin is generally considered to be subject to a lower risk of having a significant interaction with the CYP3A4-inhibiting macrolide antibiotics (erythromycin, clarithromycin, telithromycin) due to its lack of appreciable CYP3A4 metabolism.<sup>1</sup> Although specific data regarding the combination of pravastatin and erythromycin are not available, concurrent use of clarithromycin (500 mg twice/day x 9 days) with pravastatin was associated with an average 110% increase in pravastatin AUC,<sup>1</sup> suggesting that a clinically significant interaction between pravastatin and macrolides may be possible.<br><br>Considering the limited CYP3A metabolism of pravastatin, the most likely mechanism for any pravastatin-macrolide interaction is inhibition of the SLCO1B1 uptake transporter leading to reduced hepatic uptake of pravastatin. The disposition of many statins, including pravastatin, appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1), and erythromycin and other macrolides may inhibit SLCO1B1 activity.<sup>2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers Squibb Company, 10/2012.</p>\n<p>2. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>3. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>4. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p>5. Igel M, Arnold KA, Niemi M, et al, “Impact of the SLCO1B1 Polymorphism on the Pharmacokinetics and Lipid-Lowering Efficacy of Multiple-Dose Pravastatin,” <i>Clin Pharmacol Ther</i>, 2006, 79(5):419-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16678544\">[PubMed 16678544]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7673":"<p><b>Title</b> Pitavastatin / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of Pitavastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Limit pitavastatin to a maximum of 1 mg/day when used in combination with erythromycin. If this combination is used, monitor patients more closely for evidence of pitavastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> The pitavastatin AUC was an average of 2.8-fold higher with concurrent use of erythromycin (500 mg four times per day x 6 days), resulting in a recommendation in the pitavastatin prescribing information that the pitavastatin dose be limited to a maximum of 1 mg/day when used with erythromycin.<sup>1</sup><br><br>Pitavastatin is generally considered to be subject to a lower risk of having a significant interaction with the CYP3A4-inhibiting macrolide antibiotics (erythromycin, clarithromycin, telithromycin) due to its lack of appreciable CYP3A4 metabolism.<sup>1</sup> The most likely mechanism for any pitavastatin-macrolide interaction is inhibition of the SLCO1B1 uptake transporter leading to reduced hepatic uptake of pitavastatin. The disposition of many statins, including pitavastatin, appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1), and erythromycin and other macrolides may inhibit SLCO1B1 activity.<sup>2,3,4</sup> Other possible mechanisms for this interaction include alteration of the ABCG2 (BCRP)-mediated transport of pitavastatin,<sup>5,6</sup>, and/or glucuronidation of pitavastatin by UGT1A3 and UGT2B7.<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Livalo (pitavastatin). Montgomery, AL: Kowa Pharmaceuticals America, Inc., 10/2012.</p>\n<p>2. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>3. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>4. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p>5. Ieiri I, Suwannakul S, Maeda K, et al, “SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2007, 82:541-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17460607\">[PubMed 17460607]</a></p>\n<p>6. Hirano M, Maeda K, Matsushima S, et al, “Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin,” <i>Mol Pharmacol</i>, 2005, 68:800-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955871\">[PubMed 15955871]</a></p>\n<p>7. Fujino H, Yamada I, Shimada S, et al, “Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase: Human UDP-Glucuronosyltransferase Enzymes Involved in Lactonization,” <i>Xenobiotica</i>, 2003, 33:27-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12519692\">[PubMed 12519692]</a></p>\n<p>8. Yamada I, Fujino H, Shimada S, et al, “Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase: Similarities and Difference in the Metabolism of Pitavastatin in Monkeys and Humans,” <i>Xenobiotica</i>, 2003, 33:789-803. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12893526\">[PubMed 12893526]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7674":"<p><b>Title</b> Simvastatin / Telithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telithromycin may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telithromycin with simvastatin is contraindicated. Due to a possible risk of simvastatin-associated toxicities (including rhabdomyolysis), if telithromycin is needed, simvastatin should be suspended during the course of treatment.</p> \n<p><b>Discussion</b> The AUC of simvastatin and its active metabolite, simvastatin acid, were an average of 9-fold and 12-fold higher, respectively, with concurrent telithromycin.<sup>1</sup> In a separate study, the AUC of simvastatin and simvastatin acid were an average of 4-fold and 4.3-fold higher, respectively, follwoing administration of simvastatin and telithromycin 12 hours apart.<sup>1</sup><br><br>Although clinical outcomes data for this specific interaction are not available, a cohort study did report a significant increase in the risk for hospitalization due to rhabdomyolysis or acute kidney injury and an increased risk of all-cause mortality with concurrent use of simvastatin with the CYP3A4-inhibiting macrolides clarithromycin or erythromycin.<sup>2</sup><br><br>The degree to which azithromycin, largely considered a safer alternative with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>2</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>3,4</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>5</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>6</sup><br><br>Several mechanisms may contribute to this interaction. One key mechanism appears to be telithromycin inhibition of the CYP3A4-mediated metabolism of simvastatin. However, considering that the disposition of simvastatin appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1), and that telithromycin may inhibit SLCO1B1 activity, this inhibition of hepatic uptake may also contribute to this interaction to some degree.<sup>7,8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ketek (telithromycin). Bridgeport, NJ: sanofi-aventis U.S. LLC, 12/2010.</p>\n<p>2. Patel AM, Shariff S, Bailey DG, et al, “Statin Toxicity from Macrolide Antibiotic Coprescription: A Population-Based Cohort Study,” <i>Ann Intern Med</i>, 2013, 158:869-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>3. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>4. Alreja G, Inayatullah S, Goel S, et al, “Rhabdomyolysis Caused by an Unusual Interaction between Azithromycin and Simvastatin,” <i>J Cardiovasc Dis Res</i>, 2012, 3(4):319-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>5. Strandell J, Bate A, Hagg S, et al, “Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction,” <i>Br J Clin Pharmacol</i>, 2009, 68(3):427-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>6. Amsden GW, Kuye O, and Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin With Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(4):444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>7. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>8. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>9. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7675":"<p><b>Title</b> Lovastatin / Telithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telithromycin may increase the serum concentration of Lovastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telithromycin with lovastatin is contraindicated. Due to a possible risk of lovastatin-associated toxicities (including rhabdomyolysis), if telithromycin is needed, lovastatin should be suspended during the course of treatment.</p> \n<p><b>Discussion</b> Specific data on the concurrent use of lovastatin and telithromycin are not available, but a significant interaction is expected based on data with other CYP3A-inhibiting macrolides such as erythromycin and clarithromycin as well as data with telithromycin and simvastatin. The AUC of simvastatin and its active metabolite, simvastatin acid, were an average of 9-fold and 12-fold higher, respectively, with concurrent telithromycin.<sup>1</sup> In a separate study, the AUC of simvastatin and simvastatin acid were an average of 4-fold and 4.3-fold higher, respectively, follwoing administration of simvastatin and telithromycin 12 hours apart.<sup>1</sup><br><br>Although clinical outcomes data for this specific interaction are not available, a cohort study did report a significant increase in the risk for hospitalization due to rhabdomyolysis or acute kidney injury and an increased risk of all-cause mortality with concurrent use of lovastatin, simvastatin, or atorvastatin with the CYP3A4-inhibiting macrolides clarithromycin or erythromycin.<sup>2</sup><br><br>The degree to which azithromycin, largely considered a safer alternative with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>2</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>3,4</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>5</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>6</sup><br><br>Several mechanisms may contribute to this interaction. One key mechanism appears to be telithromycin inhibition of the CYP3A4-mediated metabolism of lovastatin. However, considering that the disposition of many statins appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1), and that telithromycin may inhibit SLCO1B1 activity, this inhibition of hepatic uptake may also contribute to this interaction to some degree.<sup>7,8,9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ketek (telithromycin). Bridgeport, NJ: sanofi-aventis U.S. LLC, 12/2010.</p>\n<p>2. Patel AM, Shariff S, Bailey DG, et al, “Statin Toxicity from Macrolide Antibiotic Coprescription: A Population-Based Cohort Study,” <i>Ann Intern Med</i>, 2013, 158:869-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>3. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>4. Alreja G, Inayatullah S, Goel S, et al, “Rhabdomyolysis Caused by an Unusual Interaction between Azithromycin and Simvastatin,” <i>J Cardiovasc Dis Res</i>, 2012, 3(4):319-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>5. Strandell J, Bate A, Hagg S, et al, “Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction,” <i>Br J Clin Pharmacol</i>, 2009, 68(3):427-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>6. Amsden GW, Kuye O, and Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin With Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(4):444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>7. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>8. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>9. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7676":"<p><b>Title</b> AtorvaSTATin / Telithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Telithromycin may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider limiting atorvastatin to a maximum dose of 20 mg/day when used with telithromycin. Although this is not a specific recommendation in the atorvastatin prescribing information, this is consistent with recommendations for other strong CYP3A4 inhibitors, including clarithromycin. If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> Although data specific to this combination are not available, concurrent use of clarithromycin, which is a macrolide that, like telithromycin, is strong CYP3A4 inhibitor, or erythromycin together with simvastatin, lovastatin, or atorvastatin was associated with an increased risk of hospitalization for rhabdomyolysis (RR=2.2), acute kidney injury (RR=1.8), or all-cause mortality (RR=1.6), as compared to concurrent use of azithromycin with the statins, in a cohort study of 75,858 patients on clarithromycin or erythromycin, and 68,478 patients on azithromycin.<sup>1</sup> Similarly, data with atorvastatin and clarithromycin and data with telithromycin and simvastatin, which, like atorvastatin, is a statin that is largely dependent on CYP3A metabolism for its elimination, also support a likely interaction between telithromycin and atorvastatin. The AUC of atorvastatin was increased by an average of 83% to 4.4-fold with concurrent clarithromycin.<sup>2,3</sup> The AUC of simvastatin and its active metabolite, simvastatin acid, were an average of 9-fold and 12-fold higher, respectively, with concurrent telithromycin.<sup>4</sup> In a separate study, the AUC of simvastatin and simvastatin acid were an average of 4-fold and 4.3-fold higher, respectively, following administration of simvastatin and telithromycin 12 hours apart.<sup>4</sup><br><br>The degree to which azithromycin, largely considered a safer alternative with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>1</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>5,6</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>7</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>2</sup><br><br>Several mechanisms may contribute to this anticipated interaction. One mechanism would be telithromycin inhibition of the CYP3A4-mediated metabolism of atorvastatin. However, considering that the disposition of many statins appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1),<sup>8,9,10</sup> and that telithromycin may inhibit SLCO1B1 activity, this inhibition of hepatic uptake may also contribute to this interaction to some degree.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Patel AM, Shariff S, Bailey DG, et al, “Statin Toxicity from Macrolide Antibiotic Coprescription: A Population-Based Cohort Study,” <i>Ann Intern Med</i>, 2013, 158:869-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>2. Amsden GW, Kuye O, and Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(4):444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>3. Prescribing information. Lipitor (atorvastatin). New York, NY: Pfizer Inc, 10/2012.</p>\n<p>4. Prescribing information. Ketek (telithromycin). Bridgeport, NJ: sanofi-aventis U.S. LLC, 12/2010.</p>\n<p>5. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>6. Alreja G, Inayatullah S, Goel S, et al, “Rhabdomyolysis Caused by an Unusual Interaction between Azithromycin and Simvastatin,” <i>J Cardiovasc Dis Res</i>, 2012, 3(4):319-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>7. Strandell J, Bate A, Hagg S, et al, “Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction,” <i>Br J Clin Pharmacol</i>, 2009, 68(3):427-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>8. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>9. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>10. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7677":"<p><b>Title</b> Pravastatin / Telithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Telithromycin may increase the serum concentration of Pravastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use extra caution when considering the use of telithromycin in a patient being treated with pravastatin. If this combination is used, monitor patients more closely for evidence of pravastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> Pravastatin is generally considered to be subject to a lower risk of having a significant interaction with the CYP3A4-inhibiting macrolide antibiotics (erythromycin, clarithromycin, telithromycin) due to its lack of appreciable CYP3A4 metabolism.<sup>1</sup> Although specific data regarding the combination of pravastatin and telithromycin are not available, concurrent use of clarithromycin (500 mg twice/day x 9 days) with pravastatin was associated with an average 110% increase in pravastatin AUC,<sup>1</sup> suggesting that a clinically significant interaction between pravastatin and macrolides may be possible.<br><br>Considering the limited CYP3A metabolism of pravastatin, the most likely mechanism for any pravastatin-macrolide interaction is inhibition of the SLCO1B1 uptake transporter leading to reduced hepatic uptake of pravastatin. The disposition of many statins, including pravastatin, appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1), and telithromycin and other macrolides may inhibit SLCO1B1 activity.<sup>2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers Squibb Company, 10/2012.</p>\n<p>2. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>3. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>4. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p>5. Igel M, Arnold KA, Niemi M, et al, “Impact of the SLCO1B1 Polymorphism on the Pharmacokinetics and Lipid-Lowering Efficacy of Multiple-Dose Pravastatin,” <i>Clin Pharmacol Ther</i>, 2006, 79(5):419-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16678544\">[PubMed 16678544]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7678":"<p><b>Title</b> Pitavastatin / Telithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Telithromycin may increase the serum concentration of Pitavastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use extra caution when considering the use of telithromycin in a patient being treated with pitavastatin. If this combination is used, monitor patients more closely for evidence of pitavastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> Pitavastatin is generally considered to be subject to a lower risk of having a significant interaction with the CYP3A4-inhibiting macrolide antibiotics (erythromycin, clarithromycin, telithromycin) due to its lack of appreciable CYP3A4 metabolism.<sup>1</sup> Although specific data regarding the combination of pitavastatin and telithromycin are not available, concurrent use of erythromycin (500 mg four times per day x 6 days) with pitavastatin was associated with an average 2.8-fold increase in pitavastatin AUC,<sup>1</sup> suggesting that a clinically significant interaction between pitavastatin and macrolides may be possible.<br><br>The most likely mechanism for any pitavastatin-macrolide interaction is inhibition of the SLCO1B1 uptake transporter leading to reduced hepatic uptake of pitavastatin. The disposition of many statins, including pitavastatin, appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1), and erythromycin and other macrolides may inhibit SLCO1B1 activity.<sup>2,3,4</sup> Other possible mechanisms for this interaction include alteration of the ABCG2 (BCRP)-mediated transport of pitavastatin,<sup>5,6</sup>, and/or glucuronidation of pitavastatin by UGT1A3 and UGT2B7.<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Livalo (pitavastatin). Montgomery, AL: Kowa Pharmaceuticals America, Inc., 10/2012.</p>\n<p>2. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>3. SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopathy--A Genomewide Study,” <i>N Engl J Med</i>, 2008, 359(8):789-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>4. Pasanen MK, Neuvonen M, Neuvonen PJ, et al, “SLCO1B1 Polymorphism Markedly Affects the Pharmacokinetics of Simvastatin Acid,” <i>Pharmacogenet Genomics</i>, 2006, 16(12):873-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p>5. Ieiri I, Suwannakul S, Maeda K, et al, “SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers,” <i>Clin Pharmacol Ther</i>, 2007, 82:541-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17460607\">[PubMed 17460607]</a></p>\n<p>6. Hirano M, Maeda K, Matsushima S, et al, “Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin,” <i>Mol Pharmacol</i>, 2005, 68:800-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15955871\">[PubMed 15955871]</a></p>\n<p>7. Fujino H, Yamada I, Shimada S, et al, “Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase: Human UDP-Glucuronosyltransferase Enzymes Involved in Lactonization,” <i>Xenobiotica</i>, 2003, 33:27-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12519692\">[PubMed 12519692]</a></p>\n<p>8. Yamada I, Fujino H, Shimada S, et al, “Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase: Similarities and Difference in the Metabolism of Pitavastatin in Monkeys and Humans,” <i>Xenobiotica</i>, 2003, 33:789-803. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12893526\">[PubMed 12893526]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7679":"<p><b>Title</b> Simvastatin / Azithromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use extra caution when considering the use of azithromycin together with simvastatin. Although this combination is generally considered of lower risk than combinations including clarithromycin, erythromycin, or telithromycin, interactions with azithromycin have been reported. If this combination is used, monitor patients more closely for evidence of simvastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> The degree to which azithromycin, largely considered a safer alternative to macrolides such as clarithromycin or erythromycin with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>1</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>2,3</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>4</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>5</sup><br><br>The mechanism(s) by which azithromycin would interact with a statin is unclear, as azithromycin is generally considered not to be a significant inhibitor of CYP3A4-mediated metabolism or of SLCO1B1 (OATP1B1)-mediated statin uptake.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Patel AM, Shariff S, Bailey DG, et al, “Statin Toxicity from Macrolide Antibiotic Coprescription: A Population-Based Cohort Study,” <i>Ann Intern Med</i>, 2013, 158:869-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>2. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>3. Alreja G, Inayatullah S, Goel S, et al, “Rhabdomyolysis Caused by an Unusual Interaction between Azithromycin and Simvastatin,” <i>J Cardiovasc Dis Res</i>, 2012, 3(4):319-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>4. Strandell J, Bate A, Hagg S, et al, “Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction,” <i>Br J Clin Pharmacol</i>, 2009, 68(3):427-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>5. Amsden GW, Kuye O, and Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin With Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(4):444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>6. Polasek TM, Miners JO, “Quantitative Prediction of Macrolide Drug-Drug Interaction Potential from In Vitro Studies Using Testosterone as the Human Cytochrome P4503A Substrate,” <i>Eur J Clin Pharmacol</i>, 2006, 62(3):203-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16416302\">[PubMed 16416302]</a></p>\n<p>7. Greenblatt DJ, von Moltke LL, Harmatz JS, et al, “Inhibition of Triazolam Clearance by Macrolide Antimicrobial Agents: In Vitro Correlates and Dynamic Consequences,” <i>Clin Pharmacol Ther</i>, 1998, 64(3):278-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757151\">[PubMed 9757151]</a></p>\n<p>8. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7680":"<p><b>Title</b> Lovastatin / Azithromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of Lovastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use extra caution when considering the use of azithromycin together with lovastatin. Although this combination is generally considered of lower risk than combinations including clarithromycin, erythromycin, or telithromycin, interactions with azithromycin have been reported. If this combination is used, monitor patients more closely for evidence of lovastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> The degree to which azithromycin, largely considered a safer alternative to macrolides such as clarithromycin or erythromycin with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>1</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>2,3</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>4</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>5</sup><br><br>The mechanism(s) by which azithromycin would interact with a statin is unclear, as azithromycin is generally considered not to be a significant inhibitor of CYP3A4-mediated metabolism or of SLCO1B1 (OATP1B1)-mediated statin uptake.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Patel AM, Shariff S, Bailey DG, et al, “Statin Toxicity from Macrolide Antibiotic Coprescription: A Population-Based Cohort Study,” <i>Ann Intern Med</i>, 2013, 158:869-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>2. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>3. Alreja G, Inayatullah S, Goel S, et al, “Rhabdomyolysis Caused by an Unusual Interaction between Azithromycin and Simvastatin,” <i>J Cardiovasc Dis Res</i>, 2012, 3(4):319-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>4. Strandell J, Bate A, Hagg S, et al, “Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction,” <i>Br J Clin Pharmacol</i>, 2009, 68(3):427-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>5. Amsden GW, Kuye O, and Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin With Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(4):444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>6. Polasek TM, Miners JO, “Quantitative Prediction of Macrolide Drug-Drug Interaction Potential from In Vitro Studies Using Testosterone as the Human Cytochrome P4503A Substrate,” <i>Eur J Clin Pharmacol</i>, 2006, 62(3):203-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16416302\">[PubMed 16416302]</a></p>\n<p>7. Greenblatt DJ, von Moltke LL, Harmatz JS, et al, “Inhibition of Triazolam Clearance by Macrolide Antimicrobial Agents: In Vitro Correlates and Dynamic Consequences,” <i>Clin Pharmacol Ther</i>, 1998, 64(3):278-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757151\">[PubMed 9757151]</a></p>\n<p>8. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7681":"<p><b>Title</b> AtorvaSTATin / Azithromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Azithromycin (Systemic) may enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use extra caution when considering the use of azithromycin together with atorvastatin. Although this combination is generally considered of lower risk than combinations including clarithromycin, erythromycin, or telithromycin, interactions with azithromycin have been reported. If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity (e.g., muscle aches or pains, renal dysfunction, etc.).</p> \n<p><b>Discussion</b> The degree to which azithromycin, largely considered a safer alternative to macrolides such as clarithromycin or erythromycin with respect to interactions (being considered the comparator in a large cohort study of statin-macrolide interactions<sup>1</sup>), is truly devoid of statin interactions is uncertain, as some case reports have described patients with rhabdomyolysis attributed to an interaction between azithromycin and simvastatin or lovastatin.<sup>2,3</sup> Additionally, an analysis of the WHO Collaborative Centre for International Drug Monitoring database (VigiBase) noted 58 reported cases of azithromycin-statin interactions (versus 118 for clarithromycin-statins, and 36 for erythromycin-statins), in which atorvastatin (24 cases) and simvastatin (20 cases) were the most commonly involved statins.<sup>4</sup> In contrast, one study reported no significant change in atorvastatin pharmacokinetics when given with azithromycin.<sup>5</sup><br><br>The mechanism(s) by which azithromycin would interact with a statin is unclear, as azithromycin is generally considered not to be a significant inhibitor of CYP3A4-mediated metabolism or of SLCO1B1 (OATP1B1)-mediated statin uptake.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Patel AM, Shariff S, Bailey DG, et al, “Statin Toxicity from Macrolide Antibiotic Coprescription: A Population-Based Cohort Study,” <i>Ann Intern Med</i>, 2013, 158:869-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23778904\">[PubMed 23778904]</a></p>\n<p>2. Grunden JW and Fisher KA, “Lovastatin-Induced Rhabdomyolysis Possibly Associated With Clarithromycin and Azithromycin,” <i>Ann Pharmacother</i>, 1997, 31(7-8):859-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220046\">[PubMed 9220046]</a></p>\n<p>3. Alreja G, Inayatullah S, Goel S, et al, “Rhabdomyolysis Caused by an Unusual Interaction between Azithromycin and Simvastatin,” <i>J Cardiovasc Dis Res</i>, 2012, 3(4):319-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23233778\">[PubMed 23233778]</a></p>\n<p>4. Strandell J, Bate A, Hagg S, et al, “Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction,” <i>Br J Clin Pharmacol</i>, 2009, 68(3):427-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19740401\">[PubMed 19740401]</a></p>\n<p>5. Amsden GW, Kuye O, and Wei GC, “A Study of the Interaction Potential of Azithromycin and Clarithromycin With Atorvastatin in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2002, 42(4):444-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11936570\">[PubMed 11936570]</a></p>\n<p>6. Polasek TM, Miners JO, “Quantitative Prediction of Macrolide Drug-Drug Interaction Potential from In Vitro Studies Using Testosterone as the Human Cytochrome P4503A Substrate,” <i>Eur J Clin Pharmacol</i>, 2006, 62(3):203-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16416302\">[PubMed 16416302]</a></p>\n<p>7. Greenblatt DJ, von Moltke LL, Harmatz JS, et al, “Inhibition of Triazolam Clearance by Macrolide Antimicrobial Agents: In Vitro Correlates and Dynamic Consequences,” <i>Clin Pharmacol Ther</i>, 1998, 64(3):278-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757151\">[PubMed 9757151]</a></p>\n<p>8. Seithel A, Eberl S, Singer K, et al, “The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3,” <i>Drug Metab Dispos</i>, 2007, 35(5):779-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7682":"<p><b>Title</b> Topotecan / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Topotecan. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Systemic concentrations and effects of topotecan may be reduced in patients receiving phenytoin. Monitor topotecan response closely, and consider alternatives to phenytoin when possible. No specific guidelines for topotecan dose adjustment are available.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> In a population pharmacokinetic analysis of data from 162 children given intravenous topotecan (single agent, 30 min infusion) in clinical trials, concomitant use of phenytoin was associated with an estimated average increase in topotecan lactone clearance of around 10 L/h/m2.<sup>1</sup> A patient with a median glomerular filtration rate of 63.9 mL/min and topotecan lactone clearance of around 28 L/h/m2 without phenytoin would, based on this analysis, be predicted to have a roughly 35% greater topotecan lactone clearance if given phenytoin concomitantly. Additionally, a published case report describes a 5 year old treated for medulloblastoma who had an estimated 45% higher clearance of topotecan (single agent, 30 min infusion daily for 5 days) during a chemotherapy cycle for which phenytoin was given for seizure prophylaxis (5.2 mg/kg/day for 4 weeks) compared to the following cycle given without phenytoin.<sup>2</sup> The topotecan dose was adjusted to achieve similar topotecan AUC between cycles, while N-desmethyltopotecan AUC was around 2.2 fold higher during phenytoin coadministration. The exact mechanism of this interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schaiquevich P, Panetta JC, Iacono LC, et al, “Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients,” <i>Clin Cancer Res</i>, 2007, 13(22 Pt 1):6703-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18006771\">[PubMed 18006771]</a></p>\n<p>2. Zamboni WC, Gajjar AJ, Heideman RL, et al, “Phenytoin Alters the Disposition of Topotecan and N-Desmethyl Topotecan in a Patient With Medulloblastoma,” <i>Clin Cancer Res</i>, 1998, 4(3):783-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9533548\">[PubMed 9533548]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7683":"<p><b>Title</b> Spironolactone / Cholestyramine Resin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cholestyramine Resin may enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination for signs and symptoms of metabolic acidosis and hyperkalemia.</p> \n<p><b>Discussion</b> Several published case reports describe patients who developed hyperchloremic metabolic acidosis, with or without hyperkalemia, during treatment with cholestyramine and spironolactone.<sup>1,2,3,4</sup> The patients, aged 51 to 70 years, had liver disorders and normal or mildly impaired renal function, and developed signs and symptoms consistent with hyperchloremic acidosis after receiving the combination for 1-2 months. Acidosis improved in all cases following discontinuation of one or both drugs, with or without bicarbonate administration.<br><br>An increased risk of hyperchloremic acidosis with this combination may result from the combined effects of cholestyramine (which may increase intestinal chloride-bicarbonate exchange and facilitate intestinal bicarbonate elimination) and spironolactone (which may impair renal acid elimination) on acid/base and electrolyte balance. Acidosis is expected to in turn cause an extracellular potassium shift, and spironolactone is expected to promote retention of that potassium.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Eaves ER and Korman MG, “Cholestyramine induced hyperchloremic metabolic acidosis,” <i>Aust N Z J Med</i>, 1984, 14(5):670-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6597713\">[PubMed 6597713]</a></p>\n<p>2. Clouston WM and Lloyd HM, “Cholestyramine induced hyperchloremic metabolic acidosis,” <i>Aust N Z J Med</i>, 1985, 15(2):271. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3861176\">[PubMed 3861176]</a></p>\n<p>3. Scheel PJ Jr, Whelton A, Rossiter K, et al, “Cholestyramine induced hyperchloremic metabolic acidosis,” <i>J Clin Pharmacol</i>, 1992, 32(6):536-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1634640\">[PubMed 1634640]</a></p>\n<p>4. Zapater P and Alba D, “Acidosis and Extreme Hyperkalemia Associated With Cholestyramine and Spironolactone,” <i>Ann Pharmacother</i>, 1995, 29(2):199-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7756724\">[PubMed 7756724]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7684":"<p><b>Title</b> Carisoprodol / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may increase serum concentrations of the active metabolite(s) of Carisoprodol. Specifically, Meprobamate concentrations may be increased. St John's Wort may decrease the serum concentration of Carisoprodol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider monitoring for reduced effects of carisoprodol in patients receiving St. John's wort.</p> \n<p><b>Discussion</b> Carisoprodol U.S. prescribing information highlights a potential for CYP2C19 inducing agents to decrease carisoprodol exposure and increase meprobamate exposure in carisoprodol treated patients.<sup>1</sup> St. John's wort is specifically highlighted as a potential inducing agent. The impact of this possible interaction on systemic effects of carisoprodol has not been characterized.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Soma (carisoprodol). Somerset, NJ: Meda Pharmaceuticals Inc., 2/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7685":"<p><b>Title</b> Carisoprodol / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aspirin may increase serum concentrations of the active metabolite(s) of Carisoprodol. Specifically, Meprobamate concentrations may be increased. Aspirin may decrease the serum concentration of Carisoprodol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider monitoring for reduced effects of carisoprodol in patients receiving aspirin.</p> \n<p><b>Discussion</b> Carisoprodol U.S. prescribing information highlights a potential for CYP2C19 inducing agents to decrease carisoprodol exposure and increase meprobamate exposure in carisoprodol treated patients.<sup>1</sup> “Low dose” aspirin is specifically highlighted as a potential inducing agent. The impact of this possible interaction on systemic effects of carisoprodol has not been characterized.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Soma (carisoprodol). Somerset, NJ: Meda Pharmaceuticals Inc., 2/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7686":"<p><b>Title</b> Tricyclic Antidepressants / FLUoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> FLUoxetine may enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with fluoxetine. The influence of fluoxetine may take several days or weeks to be fully resolved. Although some other selective serotonin reuptake inhibitors (SSRIs) may be less likely to have a significant pharmacokinetic interaction with specific TCAs, all would share a generally similar risk for causing serotonin syndrome, and some with a lower risk for a pharmacokinetic interaction may have an even higher risk for causing QT-interval prolongation. Despite these risks, patients who do not adequately respond to maximum doses of an SSRI may, at times, be additionally prescribed low doses of a TCA as an augmenting agent; the risks associated with such combinations are not clear.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> Several pharmacokinetic studies and published case reports have reported increased tricyclic antidepressant (TCA) concentrations and/or effects with concurrent fluoxetine, including specific reports with desipramine,<sup>1,2,3,4,5,6,7,8,9</sup> imipramine,<sup>3,10,11</sup> nortriptyline,<sup>5,12,13,14</sup> amitriptyline,<sup>11,15,16,17,18</sup> clomipramine,<sup>11,19,20,21</sup> and protriptyline.<sup>22</sup> The mechanism for these observed pharmacokinetic changes appears to be decreased TCA clearance via fluoxetine inhibition of CYP2D6-, CYP1A2-, and/or CYP2C19-mediated metabolism, as fluoxetine is a strong inhibitor of CYP2D6 and a moderate inhibitor of CYP1A2 and CYP2C19.<br><br>Of particular concern with increased TCA concentrations is the potential for increased toxicities, including serious toxicities such as serotonin syndrome or proarrhythmic effects. Many antidepressants, including fluoxetine and the TCAs, possess an ability to enhance serotonin activity, and the concomitant use of 2 or more of these agents may increase the risk of toxic effects due to central serotonergic overstimulation. The toxic effects associated with this condition may affect autonomic, neuromuscular, and cognitive function, and are termed “serotonin toxicity” or “serotonin syndrome” under some circumstances.<sup>23,24</sup> In fact, 2 published cases describe possible serotonin syndrome deemed to be at least partially related to the concurrent use of a TCA with fluoxetine.<sup>25,26</sup> Additionally, both fluoxetine<sup>27,28,29,30</sup> and many TCAs<sup>31,32,33,34</sup> have been associated with some potential to cause ECG changes, including prolongation of the QT interval. Due to questions about the clinical significance of their cardiac effects and the magnitude of their effects at therapeutic concentrations, however, both fluoxetine and the TCAs are generally considered to have some risk for prolonging the QT interval and causing proarrhythmic effects. Fluoxetine is considered in the highest risk group of QT-prolonging drugs, with its prescribing information recommending avoidance of other drugs known to prolong the QT interval, while the TCAs are generally considered to have an indeterminate degree of risk. Of note, one published case describes a clinical case of QT-prolongation attributed to a possible interaction between fluoxetine, imipramine, and levofloxacin.<sup>35</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Preskorn SH, Alderman J, Chung M, et al, “Pharmacokinetics of Desipramine Coadministered with Sertraline or Fluoxetine,” <i>J Clin Psychopharmacol</i>, 1994, 14(2):90-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8195463\">[PubMed 8195463]</a></p>\n<p>2. Wilens TE, Biederman J, Baldessarini RJ, et al, “Fluoxetine Inhibits Desipramine Metabolism,” <i>Arch Gen Psychiatry</i>, 1992, 49(9):752. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1514882\">[PubMed 1514882]</a></p>\n<p>3. Bergstrom RF, Peyton AL, Lemberger L, “Quantification and Mechanism of the Fluoxetine and Tricyclic Antidepressant Interaction,” <i>Clin Pharmacol Ther</i>, 1992, 51(3):239-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1544284\">[PubMed 1544284]</a></p>\n<p>4. Suckow RF, Roose SP, Cooper TB, “Effect of Fluoxetine on Plasma Desipramine and 2-hydroxydesipramine,” <i>Biol Psychiatry</i>, 1992, 31(2):200-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1737080\">[PubMed 1737080]</a></p>\n<p>5. von Ammon Cavanaugh S, “Drug-Drug Interactions of Fluoxetine with Tricyclics,” <i>Psychosomatics</i>, 1990, 31(3):273-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2388981\">[PubMed 2388981]</a></p>\n<p>6. DeMaso DR, Hunter TA, “Combining Fluoxetine with Desipramine,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1990, 29(1):151. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2295572\">[PubMed 2295572]</a></p>\n<p>7. Michals M, Stanley DA, Crismon ML, et al, “Elevated Tricyclic Antidepressant Plasma Concentrations Associated with Fluoxetine: Two Case Reports,” <i>J Neuropsychiatry Clin Neurosci</i>, 1990, 2(4):466-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2136405\">[PubMed 2136405]</a></p>\n<p>8. Goodnick PJ, “Influence of Fluoxetine on Plasma Levels of Desipramine,” <i>Am J Psychiatry</i>, 1989, 146(4):552. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2784633\">[PubMed 2784633]</a></p>\n<p>9. Bell IR, Cole JO, “Fluoxetine Induces Elevation of Desipramine Level and Exacerbation of Geriatric Nonpsychotic Depression,” <i>J Clin Psychopharmacol</i>, 1988, 8(6):447-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3266222\">[PubMed 3266222]</a></p>\n<p>10. Vandel S, Bertschy G, Bonin B, et al, “Tricyclic Antidepressant Plasma Levels after Fluoxetine Addition,” <i>Neuropsychobiology</i>, 1992, 25(4):202-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1454161\">[PubMed 1454161]</a></p>\n<p>11. Rosenstein DL, Takeshita J, Nelson JC, “Fluoxetine-Induced Elevation and Prolongation of Tricyclic Levels in Overdose,” <i>Am J Psychiatry</i>, 1991, 148(6):807. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2035725\">[PubMed 2035725]</a></p>\n<p>12. Benazzi F, “Venlafaxine-Fluoxetine-Nortriptyline Interaction,” <i>J Psychiatry Neurosci</i>, 1997, 22(4):278-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9262050\">[PubMed 9262050]</a></p>\n<p>13. Kahn DG, “Increased Plasma Nortriptyline Concentration in a Patient Cotreated with Fluoxetine,” <i>J Clin Psychiatry</i>, 1990, 51(1):36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2295592\">[PubMed 2295592]</a></p>\n<p>14. Schraml F, Benedetti G, Hoyle K, et al, “Fluoxetine and Nortriptyline Combination Therapy,” <i>Am J Psychiatry</i>, 1989, 146(12):1636-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2589560\">[PubMed 2589560]</a></p>\n<p>15. Preskorn SH, Baker B, “Fatality Associated with Combined Fluoxetine-Amitriptyline Therapy,” <i>JAMA</i>, 1997, 277(21):1682. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9169893\">[PubMed 9169893]</a></p>\n<p>16. el-Yazigi A, Chaleby K, Gad A, et al, “Steady-State Kinetics of Fluoxetine and Amitriptyline in Patients Treated with a Combination of These Drugs as Compared with Those Treated with Amitriptyline Alone,” <i>J Clin Pharmacol</i>, 1995, 35(1):17-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7751409\">[PubMed 7751409]</a></p>\n<p>17. Muller N, Brockmoller J, Roots I, “Extremely Long Plasma Half-Life of Amitriptyline in a Woman with the Cytochrome P450IID6 29/29-kilobase Wild-Type Allele--A Slowly Reversible Interaction with Fluoxetine,” <i>Ther Drug Monit</i>, 1991, 13(6):533-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1771652\">[PubMed 1771652]</a></p>\n<p>18. March JS, Moon RL, Johnston H, “Fluoxetine-TCA Interaction,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1990, 29(6):985-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2273036\">[PubMed 2273036]</a></p>\n<p>19. Balant-Gorgia AE, Ries C, Balant LP, “Metabolic Interaction between Fluoxetine and Clomipramine: A Case Report,” <i>Pharmacopsychiatry</i>, 1996, 29(1):38-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8852534\">[PubMed 8852534]</a></p>\n<p>20. Vandel S, Bertschy G, Baumann P, et al, “Fluvoxamine and Fluoxetine: Interaction Studies with Amitriptyline, Clomipramine and Neuroleptics in Phenotyped Patients,” <i>Pharmacol Res</i>, 1995, 31(6):347-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8685072\">[PubMed 8685072]</a></p>\n<p>21. Sternbach H, “Fluoxetine-Clomipramine Interaction,” <i>J Clin Psychiatry</i>, 1995, 56(4):171-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7713858\">[PubMed 7713858]</a></p>\n<p>22. Paul KL, Bhatara VS, “Anticholinergic Delirium Possibly Associated with Protriptyline and Fluoxetine,” <i>Ann Pharmacother</i>, 1997, 31(10):1260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9337456\">[PubMed 9337456]</a></p>\n<p>23. Dunkley EJ, Isbister GK, Sibbritt D, et al, “The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,” <i>QJM</i>, 2003, 96(9):635-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925718\">[PubMed 12925718]</a></p>\n<p>24. Sternbach H, “The Serotonin Syndrome,” <i>Am J Psychiatry</i>, 1991, 148(6):705-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2035713\">[PubMed 2035713]</a></p>\n<p>25. Power BM, Pinder M, Hackett LP, et al, “Fatal Serotonin Syndrome following a Combined Overdose of Moclobemide, Clomipramine and Fluoxetine,” <i>Anaesth Intensive Care</i>, 1995, 23(4):499-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7485947\">[PubMed 7485947]</a></p>\n<p>26. Molaie M, “Serotonin Syndrome Presenting with Migrainelike Stroke,” <i>Headache</i>, 1997, 37(8):519-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9329236\">[PubMed 9329236]</a></p>\n<p>27. Dubnov G, Fogelman R, Merlob P, “Prolonged QT Interval in an Infant of a Fluoxetine Treated Mother,” <i>Arch Dis Child</i>, 2005, 90(9):972-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16113135\">[PubMed 16113135]</a></p>\n<p>28. Wilting I, Smals OM, Holwerda NJ, et al, “QTc Prolongation and Torsades de Pointes in an Elderly Woman Taking Fluoxetine,” <i>Am J Psychiatry</i>, 2006, 163(2):325. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16449492\">[PubMed 16449492]</a></p>\n<p>29. Hancox JC, Mitcheson JS, “Combined hERG Channel Inhibition and Disruption of Trafficking in Drug-Induced Long QT Syndrome by Fluoxetine: A Case-Study in Cardiac Safety Pharmacology,” <i>Br J Pharmacol</i>, 2006, 149(5):457-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16967047\">[PubMed 16967047]</a></p>\n<p>30. Rajamani S, Eckhardt LL, Valdivia CR, et al, “Drug-Induced Long QT Syndrome: hERG K+ Channel Block and Disruption of Protein Trafficking by Fluoxetine and Norfluoxetine,” <i>Br J Pharmacol</i>, 2006, 149(5):481-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16967046\">[PubMed 16967046]</a></p>\n<p>31. Okayasu H, Ozeki Y, Fujii K, et al, “Pharmacotherapeutic Determinants for QTc Interval Prolongation in Japanese Patients with Mood Disorder,” <i>Pharmacopsychiatry</i>, 2012, 45(7):279-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22592502\">[PubMed 22592502]</a></p>\n<p>32. van Noord C, Straus SM, Sturkenboom MC, et al, “Psychotropic Drugs Associated with Corrected QT Interval Prolongation,” <i>J Clin Psychopharmacol</i>, 2009, 29(1):9-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19142100\">[PubMed 19142100]</a></p>\n<p>33. Goodnick PJ, Jerry J, Parra F, “Psychotropic Drugs and the ECG: Focus on the QTc Interval,” <i>Expert Opin Pharmacother</i>, 2002, 3(5):479-98. (review) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11996627\">[PubMed 11996627]</a></p>\n<p>34. Rodriguez de la Torre B, Dreher J, Malevany I, et al, “Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients,” <i>Ther Drug Monit</i>, 2001, 23(4):435-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11477329\">[PubMed 11477329]</a></p>\n<p>35. Nykamp DL, Blackmon CL, Schmidt PE, et al, “QTc Prolongation Associated with Combination Therapy of Levofloxacin, Imipramine, and Fluoxetine,” <i>Ann Pharmacother</i>, 2005, 39(3):543-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15687478\">[PubMed 15687478]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7687":"<p><b>Title</b> Tricyclic Antidepressants / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> FluvoxaMINE may enhance the adverse/toxic effect of Tricyclic Antidepressants. FluvoxaMINE may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with fluvoxamine. The influence of fluvoxamine may take several days to be fully resolved. Although some other selective serotonin reuptake inhibitors (SSRIs) may be less likely to have a significant pharmacokinetic interaction with specific TCAs, all would share a generally similar risk for causing serotonin syndrome, and some with a lower risk for a pharmacokinetic interaction may have an even higher risk for causing QT-interval prolongation. Despite these risks, patients who do not adequately respond to maximum doses of an SSRI may, at times, be additionally prescribed low doses of a TCA as an augmenting agent; the risks associated with such combinations are not clear.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> Several pharmacokinetic studies and published case reports have reported increased tricyclic antidepressant (TCA) concentrations and/or effects with concurrent fluvoxamine, including specific reports with clomipramine,<sup>1,2,3</sup> trimipramine,<sup>4</sup> amitriptyline,<sup>1</sup> imipramine,<sup>5,6,7,8,9</sup> and desipramine.<sup>5,6,7</sup> Of note, the magnitude of this interaction appears to vary somewhat according to the specific TCA involved, with the impact reportedly greater with tertiary (e.g., imipramine) vs. secondary (e.g., desipramine) amine TCAs.<sup>5,6</sup> The mechanism for these observed pharmacokinetic changes appears to be decreased TCA clearance,<sup>10</sup> likely via fluvoxamine inhibition of the CYP1A2 and/or CYP2C19, as fluvoxamine is a strong inhibitor of CYP1A2 and CYP2C19,<sup>11,12,13,14,15</sup> and most TCAs are at least partially metabolized by CYP1A2 and/or CYP2C19.<br><br>Of particular concern with increased TCA concentrations is the potential for increased toxicities, including serious toxicities such as serotonin syndrome or proarrhythmic effects. Many antidepressants, including fluvoxamine and the TCAs, possess an ability to enhance serotonin activity. Excessive serotonergic stimulation can cause clinically unwanted effects, and both fluvoxamine and several individual TCAs have been associated with such toxicity.<sup>16,17,18,19</sup> The toxic effects associated with this condition may affect autonomic, neuromuscular, and cognitive function, and are termed “serotonin toxicity” or “serotonin syndrome” under some circumstances.<sup>16,17</sup> Concomitant use of 2 or more of these agents may increase the risk of toxic effects due to central serotonergic overstimulation. Additionally, many TCAs<sup>20,21,22,23</sup> have been associated with some potential to cause ECG changes, including prolongation of the QT interval and/or torsades de pointes. Due to questions about the clinical significance of their cardiac effects and the magnitude of their effects at therapeutic concentrations, however, fluvoxamine is not considered to have a clinically meaningful impact on the QT interval, and the TCAs are generally considered to have an indeterminate risk for prolonging the QT interval and causing proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vandel S, Bertschy G, Baumann P, et al, “Fluvoxamine and Fluoxetine: Interaction Studies with Amitriptyline, Clomipramine and Neuroleptics in Phenotyped Patients,” <i>Pharmacol Res</i>, 1995, 31(6):347-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8685072\">[PubMed 8685072]</a></p>\n<p>2. Szegedi A, Wetzel H, Leal M, et al, “Combination Treatment with Clomipramine and Fluvoxamine: Drug Monitoring, Safety, and Tolerability Data,” <i>J Clin Psychiatry</i>, 1996, 57(6):257-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8666564\">[PubMed 8666564]</a></p>\n<p>3. Conus P, Bondolfi G, Eap CB, et al, “Pharmacokinetic Fluvoxamine-Clomipramine Interaction with Favorable Therapeutic Consequences in Therapy-Resistant Depressive Patient,” <i>Pharmacopsychiatry</i>, 1996, 29(3):108-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8738315\">[PubMed 8738315]</a></p>\n<p>4. Seifritz E, Holsboer-Trachsler E, Hemmeter U, et al, “Increased Trimipramine Plasma Levels during Fluvoxamine Comedication,” <i>Eur Neuropsychopharmacol</i>, 1994, 4(1):15-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8204992\">[PubMed 8204992]</a></p>\n<p>5. Spina E, Pollicino AM, Avenoso A, et al, “Effect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects,” <i>Ther Drug Monit</i>, 1993, 15(3):243-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8333005\">[PubMed 8333005]</a></p>\n<p>6. Spina E, Pollicino AM, Avenoso A, et al, “Fluvoxamine-Induced Alterations in Plasma Concentrations of Imipramine and Desipramine in Depressed Patients,” <i>Int J Clin Pharmacol Res</i>, 1993, 13(3):167-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8225700\">[PubMed 8225700]</a></p>\n<p>7. Spina E, Campo GM, Avenoso A, et al, “Interaction between Fluvoxamine and Imipramine/Desipramine in Four Patients,” <i>Ther Drug Monit</i>, 1992, 14(3):194-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1412604\">[PubMed 1412604]</a></p>\n<p>8. Xu ZH, Huang SL, Zhou HH, “Inhibition of Imipramine N-demethylation by Fluvoxamine in Chinese Young Men,” <i>Zhongguo Yao Li Xue Bao</i>, 1996, 17(5):399-402. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9863158\">[PubMed 9863158]</a></p>\n<p>9. Maskall DD, Lam RW, “Increased Plasma Concentration of Imipramine following Augmentation with Fluvoxamine,” <i>Am J Psychiatry</i>, 1993, 150(10):1566. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8379574\">[PubMed 8379574]</a></p>\n<p>10. Hartter S, Wetzel H, Hammes E, et al, “Inhibition of Antidepressant Demethylation and Hydroxylation by Fluvoxamine in Depressed Patients,” <i>Psychopharmacology (Berl)</i>, 1993, 110(3):302-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7831423\">[PubMed 7831423]</a></p>\n<p>11. Brosen K, Skjelbo E, Rasmussen BB, et al, “Fluvoxamine is a Potent Inhibitor of Cytochrome P4501A2,” <i>Biochem Pharmacol</i>, 1993, 45(6):1211-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8466541\">[PubMed 8466541]</a></p>\n<p>12. Jeppesen U, Gram LF, Vistisen K, et al, “Dose-Dependent Inhibition of CYP1A2, CYP2C19 and CYP2D6 by Citalopram, Fluoxetine, Fluvoxamine and Paroxetine,” <i>Eur J Clin Pharmacol</i>, 1996, 51(1):73-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8880055\">[PubMed 8880055]</a></p>\n<p>13. Jeppesen U, Rasmussen BB, Brosen K, “Fluvoxamine Inhibits the CYP2C19-Catalyzed Bioactivation of Chloroguanide,” <i>Clin Pharmacol Ther</i>, 1997, 62(3):279-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9333103\">[PubMed 9333103]</a></p>\n<p>14. Yao C, Kunze KL, Trager WF, et al, “Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19,” <i>Drug Metab Dispos</i>, 2003, 31(5):565-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12695344\">[PubMed 12695344]</a></p>\n<p>15. Christensen M, Tybring G, Mihara K, et al, “Low Daily 10-mg and 20-mg Doses of Fluvoxamine Inhibit the Metabolism of both Caffeine (Cytochrome P4501A2) and Omeprazole (Cytochrome P4502C19),” <i>Clin Pharmacol Ther</i>, 2002, 71(3):141-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11907488\">[PubMed 11907488]</a></p>\n<p>16. Dunkley EJ, Isbister GK, Sibbritt D, et al, “The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,” <i>QJM</i>, 2003, 96(9):635-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925718\">[PubMed 12925718]</a></p>\n<p>17. Sternbach H, “The Serotonin Syndrome,” <i>Am J Psychiatry</i>, 1991, 148(6):705-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2035713\">[PubMed 2035713]</a></p>\n<p>18. Bastani JB, Troester MM, Bastani AJ, “Serotonin Syndrome and Fluvoxamine: A Case Study,” <i>Nebr Med J</i>, 1996, 81(4):107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8628448\">[PubMed 8628448]</a></p>\n<p>19. Kaneda Y, Ishimoto Y, Ohmori T, “Mild Serotonin Syndrome on Fluvoxamine,” <i>Int J Neurosci</i>, 2001, 109(3-4):165-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11699328\">[PubMed 11699328]</a></p>\n<p>20. Okayasu H, Ozeki Y, Fujii K, et al, “Pharmacotherapeutic Determinants for QTc Interval Prolongation in Japanese Patients with Mood Disorder,” <i>Pharmacopsychiatry</i>, 2012, 45(7):279-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22592502\">[PubMed 22592502]</a></p>\n<p>21. van Noord C, Straus SM, Sturkenboom MC, et al, “Psychotropic Drugs Associated with Corrected QT Interval Prolongation,” <i>J Clin Psychopharmacol</i>, 2009, 29(1):9-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19142100\">[PubMed 19142100]</a></p>\n<p>22. Goodnick PJ, Jerry J, Parra F, “Psychotropic Drugs and the ECG: Focus on the QTc Interval,” <i>Expert Opin Pharmacother</i>, 2002, 3(5):479-98. (review) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11996627\">[PubMed 11996627]</a></p>\n<p>23. Rodriguez de la Torre B, Dreher J, Malevany I, et al, “Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients,” <i>Ther Drug Monit</i>, 2001, 23(4):435-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11477329\">[PubMed 11477329]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7688":"<p><b>Title</b> Tricyclic Antidepressants / PARoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> PARoxetine may enhance the adverse/toxic effect of Tricyclic Antidepressants. PARoxetine may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with paroxetine. The influence of paroxetine may take several days to be fully resolved. Although some other selective serotonin reuptake inhibitors (SSRIs) may be less likely to have a significant pharmacokinetic interaction with specific TCAs, all would share a generally similar risk for causing serotonin syndrome, and some with a lower risk for a pharmacokinetic interaction may have an even higher risk for causing QT-interval prolongation. Despite these risks, patients who do not adequately respond to maximum doses of an SSRI may, at times, be additionally prescribed low doses of a TCA as an augmenting agent; the risks associated with such combinations are not clear.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> Several pharmacokinetic studies and published case reports have reported increased tricyclic antidepressant (TCA) concentrations and/or effects with concurrent paroxetine, including specific reports with desipramine,<sup>1,2,3,4,5</sup> imipramine,<sup>1,2</sup> nortriptyline,<sup>1,6</sup> and amitriptyline.<sup>1</sup> The mechanism for these observed pharmacokinetic changes appears to be decreased TCA clearance via paroxetine inhibition of CYP2D6-mediated metabolism, as paroxetine is a strong inhibitor of CYP2D6, and most TCAs are at least partially metabolized by CYP2D6.<br><br>Of particular concern with increased TCA concentrations is the potential for increased toxicities, including serious toxicities such as serotonin syndrome or proarrhythmic effects. Many antidepressants, including paroxetine and the TCAs, possess an ability to enhance serotonin activity, and the concomitant use of 2 or more of these agents may increase the risk of toxic effects due to central serotonergic overstimulation. The toxic effects associated with this condition may affect autonomic, neuromuscular, and cognitive function, and are termed “serotonin toxicity” or “serotonin syndrome” under some circumstances.<sup>7,8</sup> In fact, one published case describes possible serotonin syndrome deemed to be at least partially related to the concurrent use of imipramine with paroxetine.<sup>9</sup> Additionally, both paroxetine<sup>10,11,12</sup> and many TCAs<sup>13,14,15,16</sup> have been associated with some potential to cause ECG changes, including prolongation of the QT interval and/or torsades de pointes. Due to questions about the clinical significance of their cardiac effects and the magnitude of their effects at therapeutic concentrations, however, both paroxetine and the TCAs are generally considered to have an indeterminate risk for prolonging the QT interval and causing proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Leucht S, Hackl HJ, Steimer W, et al, “Effect of Adjunctive Paroxetine on Serum Levels and Side-Effects of Tricyclic Antidepressants in Depressive Inpatients,” <i>Psychopharmacology (Berl)</i>, 2000, 147(4):378-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10672631\">[PubMed 10672631]</a></p>\n<p>2. Albers LJ, Reist C, Helmeste D, et al, “Paroxetine Shifts Imipramine Metabolism,” <i>Psychiatry Res</i>, 1996, 59(3):189-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8930024\">[PubMed 8930024]</a></p>\n<p>3. Brosen K, Hansen JG, Nielsen KK, et al, “Inhibition by Paroxetine of Desipramine Metabolism in Extensive but Not in Poor Metabolizers of Sparteine,” <i>Eur J Clin Pharmacol</i>, 1993, 44(4):349-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8513845\">[PubMed 8513845]</a></p>\n<p>4. Alderman J, Preskorn SH, Greenblatt DJ, et al, “Desipramine Pharmacokinetics when Coadministere d with Paroxetine or Sertraline in Extensive Metabolizers,” <i>J Clin Psychopharmacol</i>, 1997, 17(4):284-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241008\">[PubMed 9241008]</a></p>\n<p>5. Nichols AI, Fatato P, Shenouda M, et al, “The Effects of Desvenlafaxine and Paroxetine on the Pharmacokinetics of the Cytochrome P450 2D6 Substrate Desipramine in Healthy Adults,” <i>J Clin Pharmacol</i>, 2009, 49(2):219-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19001559\">[PubMed 19001559]</a></p>\n<p>6. Ghaemi SN, Kirkwood CK, “Elevation of Nortriptyline Plasma Levels after Cotreatment with Paroxetine and Thioridazine,” <i>J Clin Psychopharmacol</i>, 1998, 18(4):342-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9690702\">[PubMed 9690702]</a></p>\n<p>7. Dunkley EJ, Isbister GK, Sibbritt D, et al, “The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,” <i>QJM</i>, 2003, 96(9):635-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925718\">[PubMed 12925718]</a></p>\n<p>8. Sternbach H, “The Serotonin Syndrome,” <i>Am J Psychiatry</i>, 1991, 148(6):705-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2035713\">[PubMed 2035713]</a></p>\n<p>9. Weiner AL, Tilden FF Jr, McKay CA Jr, “Serotonin Syndrome: Case Report and Review of the Literature,” <i>Conn Med</i>, 1997, 61(11):717-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9419960\">[PubMed 9419960]</a></p>\n<p>10. Erfurth A, Loew M, Dobmeier P, et al, “[ECG Changes After Paroxetine. 3 Case Reports],” <i>Nervenarzt</i>, 1998, 69(7):629-31. (article in German) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9715482\">[PubMed 9715482]</a></p>\n<p>11. Astrom-Lilja C, Odeberg JM, Ekman E, et al, “Drug-Induced Torsades de Pointes: A Review of the Swedish Pharmacovigilance Database,” <i>Pharmacoepidemiol Drug Saf</i>, 2008, 17(6):587-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18449951\">[PubMed 18449951]</a></p>\n<p>12. Poluzzi E, Raschi E, Moretti U, et al, “Drug-Induced Torsades de Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS),” <i>Pharmacoepidemiol Drug Saf</i>, 2009, 18(6):512-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19358226\">[PubMed 19358226]</a></p>\n<p>13. Okayasu H, Ozeki Y, Fujii K, et al, “Pharmacotherapeutic Determinants for QTc Interval Prolongation in Japanese Patients with Mood Disorder,” <i>Pharmacopsychiatry</i>, 2012, 45(7):279-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22592502\">[PubMed 22592502]</a></p>\n<p>14. van Noord C, Straus SM, Sturkenboom MC, et al, “Psychotropic Drugs Associated with Corrected QT Interval Prolongation,” <i>J Clin Psychopharmacol</i>, 2009, 29(1):9-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19142100\">[PubMed 19142100]</a></p>\n<p>15. Goodnick PJ, Jerry J, Parra F, “Psychotropic Drugs and the ECG: Focus on the QTc Interval,” <i>Expert Opin Pharmacother</i>, 2002, 3(5):479-98. (review) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11996627\">[PubMed 11996627]</a></p>\n<p>16. Rodriguez de la Torre B, Dreher J, Malevany I, et al, “Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients,” <i>Ther Drug Monit</i>, 2001, 23(4):435-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11477329\">[PubMed 11477329]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7689":"<p><b>Title</b> Tricyclic Antidepressants / Sertraline</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sertraline may enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with sertraline. The influence of sertraline may take several days to be fully resolved. Although some other selective serotonin reuptake inhibitors (SSRIs) may be less likely to have a significant pharmacokinetic interaction with specific TCAs, all would share a generally similar risk for causing serotonin syndrome, and some with a lower risk for a pharmacokinetic interaction may have an even higher risk for causing QT-interval prolongation. Despite these risks, patients who do not adequately respond to maximum doses of an SSRI may, at times, be additionally prescribed low doses of a TCA as an augmenting agent; the risks associated with such combinations are not clear.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> Several pharmacokinetic studies and published case reports have reported increased tricyclic antidepressant (TCA) concentrations and/or effects with concurrent sertraline.<sup>1,2,3,4,5,6</sup> Desipramine concentrations have been reportedly increased by 23-60% with concurrent sertraline.<sup>1,2,3,4</sup> Similarly, imipramine concentrations were an average of 68% higher with sertraline.<sup>1</sup> Low-dose sertraline had only a minor impact on the median nortriptyline concentration, but considerable inter-individual variation was noted, with some reporting more than a 50% increase in nortriptyline concentrations.<sup>5</sup> Higher-dose sertraline increased median nortriptyline concentrations by 40%.<sup>5</sup> The mechanism for these observed pharmacokinetic changes appears to be decreased TCA clearance via sertraline inhibition of the CYP2D6- and/or CYP2C19-mediated metabolism of individual TCAs, as sertraline is a mild-moderate inhibitor of CYP2D6 and CYP2C19, and most TCAs are at least partially metabolized by CYP2D6 and/or CYP2C19.<br><br>Of particular concern with increased TCA concentrations is the potential for increased toxicities, including serious toxicities such as serotonin syndrome or proarrhythmic effects. Many antidepressants, including sertraline and the TCAs, possess an ability to enhance serotonin activity, and the concomitant use of 2 or more of these agents may increase the risk of toxic effects due to central serotonergic overstimulation. The toxic effects associated with this condition may affect autonomic, neuromuscular, and cognitive function, and are termed “serotonin toxicity” or “serotonin syndrome” under some circumstances.<sup>7,8</sup> In fact, one published case describes possible serotonin syndrome deemed to be at least partially related to the concurrent use of amitriptyline with sertraline.<sup>9</sup> Additionally, both sertraline<sup>10,11</sup> and many TCAs<sup>12,13,14,15</sup> have been associated with some potential to cause ECG changes, including prolongation of the QT interval and/or torsades de pointes. Due to questions about the clinical significance of their cardiac effects and the magnitude of their effects at therapeutic concentrations, however, both sertraline and the TCAs are generally considered to have an indeterminate risk for prolonging the QT interval and causing proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kurtz DL, Bergstrom RF, Goldberg MJ, et al, “The Effect of Sertraline on the Pharmacokinetics of Desipramine and Imipramine,” <i>Clin Pharmacol Ther</i>, 1997, 62(2):145-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9284850\">[PubMed 9284850]</a></p>\n<p>2. Preskorn SH, Alderman J, Chung M, et al, “Pharmacokinetics of Desipramine Coadministered with Sertraline or Fluoxetine,” <i>J Clin Psychopharmacol</i>, 1994, 14(2):90-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8195463\">[PubMed 8195463]</a></p>\n<p>3. Alderman J, Preskorn SH, Greenblatt DJ, et al, “Desipramine Pharmacokinetics when Coadministered with Paroxetine or Sertraline in Extensive Metabolizers,” <i>J Clin Psychopharmacol</i>, 1997, 17(4):284-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241008\">[PubMed 9241008]</a></p>\n<p>4. Lydiard RB, Anton RF, Cunningham T, “Interactions between Sertraline and Tricyclic Antidepressants,” <i>Am J Psychiatry</i>, 1993, 150(7):1125-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8317590\">[PubMed 8317590]</a></p>\n<p>5. Solai LK, Mulsant BH, Pollock BG, et al, “Effect of Sertraline on Plasma Nortriptyline Levels in Depressed Elderly,” <i>J Clin Psychiatry</i>, 1997, 58(10):440-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9375595\">[PubMed 9375595]</a></p>\n<p>6. Barros J, Asnis G, “An Interaction of Sertraline and Desipramine,” <i>Am J Psychiatry</i>, 1993, 150(11):1751. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8214190\">[PubMed 8214190]</a></p>\n<p>7. Dunkley EJ, Isbister GK, Sibbritt D, et al, “The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,” <i>QJM</i>, 2003, 96(9):635-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925718\">[PubMed 12925718]</a></p>\n<p>8. Sternbach H, “The Serotonin Syndrome,” <i>Am J Psychiatry</i>, 1991, 148(6):705-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2035713\">[PubMed 2035713]</a></p>\n<p>9. Alderman CP, Lee PC, “Comment: Serotonin Syndrome Associated with Combined Sertraline-Amitriptyline Treatment,” <i>Ann Pharmacother</i>, 1996, 30(12):1499-500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8968471\">[PubMed 8968471]</a></p>\n<p>10. de Boer RA, van Dijk TH, Holman ND, et al, “QT Interval Prolongation after Sertraline Overdose: A Case Report,” <i>BMC Emerg Med</i>, 2005, 5:5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16029494\">[PubMed 16029494]</a></p>\n<p>11. Hoehns JD, Fouts MM, Kelly MW, et al, “Sudden Cardiac Death with Clozapine and Sertraline Combination,” <i>Ann Pharmacother</i>, 2001, 35(7-8):862-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11485134\">[PubMed 11485134]</a></p>\n<p>12. Okayasu H, Ozeki Y, Fujii K, et al, “Pharmacotherapeutic Determinants for QTc Interval Prolongation in Japanese Patients with Mood Disorder,” <i>Pharmacopsychiatry</i>, 2012, 45(7):279-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22592502\">[PubMed 22592502]</a></p>\n<p>13. van Noord C, Straus SM, Sturkenboom MC, et al, “Psychotropic Drugs Associated with Corrected QT Interval Prolongation,” <i>J Clin Psychopharmacol</i>, 2009, 29(1):9-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19142100\">[PubMed 19142100]</a></p>\n<p>14. Goodnick PJ, Jerry J, Parra F, “Psychotropic Drugs and the ECG: Focus on the QTc Interval,” <i>Expert Opin Pharmacother</i>, 2002, 3(5):479-98. (review) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11996627\">[PubMed 11996627]</a></p>\n<p>15. Rodriguez de la Torre B, Dreher J, Malevany I, et al, “Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients,” <i>Ther Drug Monit</i>, 2001, 23(4):435-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11477329\">[PubMed 11477329]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7690":"<p><b>Title</b> Citalopram / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the adverse/toxic effect of Citalopram. Tricyclic Antidepressants may increase the serum concentration of Citalopram. Citalopram may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with citalopram. Although citalopram is one of the selective serotonin reuptake inhibitors (SSRIs) that is least likely to have a significant pharmacokinetic interaction with specific TCAs, its potential for a pharmacodynamic interaction leading to an increased risk for serotonin syndrome is likely similar to that with other SSRIs. Also, citalopram has one of the highest risks among the SSRIs for causing QT-interval prolongation, leading to a potentially significant increase in the risk for excessive QT prolongation and proarrhythmia with concurrent use of a TCA. Despite these risks, patients who do not adequately respond to maximum doses of an SSRI may, at times, be additionally prescribed low doses of a TCA as an augmenting agent; the risks associated with such combinations are not clear.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> Though some pharmacokinetic studies and/or published case reports have reported increased tricyclic antidepressant (TCA) concentrations and/or effects with concurrent citalopram,<sup>1,2,3,4</sup> this is thought to be one of the SSRIs least likely to alter the metabolism of other drugs. The best documented reported interactions are with desipramine, where citalopram has been associated with a 14-50% increase in desipramine concentrations.<sup>1,2</sup> In contrast, data with amitriptyline and its active metabolite nortriptyline suggest no significant interaction with citalopram.<sup>5</sup> Any impact of citalopram on the pharmacokinetics of desipramine or other TCAs is likely the result of citalopram inhibition of the CYP2D6-mediated metabolism of the TCA, as citalopram is a weak inhibitor of CYP2D6.<br><br>Of interest, data from 18 patients treated with citalopram in addition to a TCA revealed that average citalopram concentrations were 44% higher and average desmethylcitalopram concentrations were 111% higher, suggesting that TCAs may increase citalopram exposure.<sup>6</sup> The specific mechanism(s) responsible for this possible interaction is(are) unclear.<br><br>Of particular concern with increased TCA and/or citalopram concentrations is the potential for increased toxicities, including serious toxicities such as serotonin syndrome or proarrhythmic effects. Many antidepressants, including citalopram and the TCAs, possess an ability to enhance serotonin activity. Excessive serotonergic stimulation can cause clinically unwanted effects, and both citalopram and several individual TCAs have been associated with such toxicity.<sup>7,8,9,10,11</sup> The toxic effects associated with this condition may affect autonomic, neuromuscular, and cognitive function, and are termed “serotonin toxicity” or “serotonin syndrome” under some circumstances.<sup>7,8</sup> Concomitant use of 2 or more of these agents may increase the risk of toxic effects due to central serotonergic overstimulation. <br><br>Additionally, both citalopram<sup>12,13,14,15,16,17,18,19</sup> and many TCAs<sup>20,21,22,23</sup> have been associated with some potential to cause ECG changes, including prolongation of the QT interval and/or torsades de pointes. Due to questions about the clinical significance of their cardiac effects and the magnitude of their effects at therapeutic concentrations, the TCAs are generally considered to have an indeterminate risk for prolonging the QT interval and causing proarrhythmic effects. In contrast, citalopram is generally classified as having a high risk for prolonging the QT interval and causing proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gram LF, Hansen MG, Sindrup SH, et al, “Citalopram: Interaction Studies with Levomepromazine, Imipramine, and Lithium,” <i>Ther Drug Monit</i>, 1993, 15(1):18-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8451775\">[PubMed 8451775]</a></p>\n<p>2. Gupta S, Masand PS, “Effect of Citalopram on Blood Desipramine Levels,” <i>Prim Care Companion J Clin Psychiatry</i>, 2000, 2(1):28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15014667\">[PubMed 15014667]</a></p>\n<p>3. Haffen E, Vandel P, Broly F, et al, “Citalopram: An Interaction Study with Clomipramine in a Patient Heterozygous for CYP2D6 Genotype,” <i>Pharmacopsychiatry</i>, 1999, 32(6):232-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10599932\">[PubMed 10599932]</a></p>\n<p>4. Musshoff F, Schmidt P, Madea B, “Fatality Caused by a Combined Trimipramine-Citalopram Intoxication,” <i>Forensic Sci Int</i>, 1999, 106(2):125-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10664899\">[PubMed 10664899]</a></p>\n<p>5. Baettig D, Bondolfi G, Montaldi S, et al, “Tricyclic Antidepressant Plasma Levels after Augmentation with Citalopram: A Case Study,” <i>Eur J Clin Pharmacol</i>, 1993, 44(4):403-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8513856\">[PubMed 8513856]</a></p>\n<p>6. Leinonen E, Lepola U, Koponen H, et al, “The Effect of Age and Concomitant Treatment with Other Psychoactive Drugs on Serum Concentrations of Citalopram Measured with a Nonenantioselective Method,” <i>Ther Drug Monit</i>, 1996, 18(2):111-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8721271\">[PubMed 8721271]</a></p>\n<p>7. Dunkley EJ, Isbister GK, Sibbritt D, et al, “The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,” <i>QJM</i>, 2003, 96(9):635-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925718\">[PubMed 12925718]</a></p>\n<p>8. Sternbach H, “The Serotonin Syndrome,” <i>Am J Psychiatry</i>, 1991, 148(6):705-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2035713\">[PubMed 2035713]</a></p>\n<p>9. Turedi S, Eraydin I, Gunduz A, et al, “First Time, Low Dose Citalopram Use-Related Serotonin Syndrome,” <i>Neurotoxicology</i>, 2007, 28(6):1272-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18213744\">[PubMed 18213744]</a></p>\n<p>10. Tomaselli G, Modestin J, “Repetition of Serotonin Syndrome after Reexposure to SSRI--A Case Report,” <i>Pharmacopsychiatry</i>, 2004, 37(5):236-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15359377\">[PubMed 15359377]</a></p>\n<p>11. Voirol P, Hodel PF, Zullino D, et al, “Serotonin Syndrome after Small Doses of Citalopram or Sertraline,” <i>J Clin Psychopharmacol</i>, 2000, 20(6):713-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11106153\">[PubMed 11106153]</a></p>\n<p>12. Castro VM, Clements CC, Murphy SN, et al, “QT Interval and Antidepressant Use: A Cross Sectional Study of Electronic Health Records,” <i>BMJ</i>, 2013, 346:f288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23360890\">[PubMed 23360890]</a></p>\n<p>13. Deshmukh A, Ulveling K, Alla V, et al, “Prolonged QTc Interval and Torsades de Pointes Induced by Citalopram,” <i>Tex Heart Inst J</i>, 2012, 39(1):68-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22412232\">[PubMed 22412232]</a></p>\n<p>14. Fayssoil A, Issi J, Guerbaa M, et al, “Torsade de Pointes Induced by Citalopram and Amiodarone,” <i>Ann Cardiol Angeiol (Paris)</i>, 2011, 60(3):165-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21295285\">[PubMed 21295285]</a></p>\n<p>15. Jimmink A, Caminada K, Hunfeld NG, et al, “Clinical Toxicology of Citalopram after Acute Intoxication with the Sole Drug or in Combination with Other Drugs: Overview of 26 Cases,” <i>Ther Drug Monit</i>, 2008, 30(3):365-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18520609\">[PubMed 18520609]</a></p>\n<p>16. Astrom-Lilja C, Odeberg JM, Ekman E, et al, “Drug-Induced Torsades de Pointes: A Review of the Swedish Pharmacovigilance Database,” <i>Pharmacoepidemiol Drug Saf</i>, 2008, 17(6):587-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18449951\">[PubMed 18449951]</a></p>\n<p>17. Poluzzi E, Raschi E, Moretti U, et al, “Drug-Induced Torsades de Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS),” <i>Pharmacoepidemiol Drug Saf</i>, 2009, 18(6):512-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19358226\">[PubMed 19358226]</a></p>\n<p>18. Blaschke D, Parwani AS, Huemer M, et al, “Torsade de Pointes during Combined Treatment with Risperidone and Citalopram,” <i>Pharmacopsychiatry</i>, 2007, 40(6):294-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18030657\">[PubMed 18030657]</a></p>\n<p>19. Kanjanauthai S, Kanluen T, Chareonthaitawee P, “Citalopram Induced Torsade de Pointes, a Rare Life Threatening Side Effect,” <i>Int J Cardiol</i>, 2008, 131(1):e33-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17919753\">[PubMed 17919753]</a></p>\n<p>20. Okayasu H, Ozeki Y, Fujii K, et al, “Pharmacotherapeutic Determinants for QTc Interval Prolongation in Japanese Patients with Mood Disorder,” <i>Pharmacopsychiatry</i>, 2012, 45(7):279-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22592502\">[PubMed 22592502]</a></p>\n<p>21. van Noord C, Straus SM, Sturkenboom MC, et al, “Psychotropic Drugs Associated with Corrected QT Interval Prolongation,” <i>J Clin Psychopharmacol</i>, 2009, 29(1):9-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19142100\">[PubMed 19142100]</a></p>\n<p>22. Goodnick PJ, Jerry J, Parra F, “Psychotropic Drugs and the ECG: Focus on the QTc Interval,” <i>Expert Opin Pharmacother</i>, 2002, 3(5):479-98. (review) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11996627\">[PubMed 11996627]</a></p>\n<p>23. Rodriguez de la Torre B, Dreher J, Malevany I, et al, “Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients,” <i>Ther Drug Monit</i>, 2001, 23(4):435-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11477329\">[PubMed 11477329]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7691":"<p><b>Title</b> Escitalopram / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the adverse/toxic effect of Escitalopram. Escitalopram may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with escitalopram. Although escitalopram is one of the selective serotonin reuptake inhibitors (SSRIs) that is least likely to have a significant pharmacokinetic interaction with specific TCAs, its potential for a pharmacodynamic interaction leading to an increased risk for serotonin syndrome is likely similar to that with other SSRIs. Also, escitalopram has one of the highest risks among the SSRIs for causing QT-interval prolongation, leading to a potentially significant increase in the risk for excessive QT prolongation and proarrhythmia with concurrent use of a TCA. Despite these risks, patients who do not adequately respond to maximum doses of an SSRI may, at times, be additionally prescribed low doses of a TCA as an augmenting agent; the risks associated with such combinations are not clear.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> The desipramine AUC was increased by an average of 100% when desipramine (50 mg x 1 dose) was given with escitalopram (20 mg/day x 21 days).<sup>1</sup> Other data concerning the potential pharmacokinetic interaction between escitalopram and tricyclic antidepressants (TCAs) are not available, but considering that escitalopram is a single enantiomer version of the racemic citalopram, data with citalopram are expected to be similar to what would be seen with escitalopram. Though some pharmacokinetic studies and/or published case reports have reported increased TCA concentrations and/or effects with concurrent citalopram,<sup>2,3,4,5</sup> both citalopram and escitalopram are thought to be among the SSRIs least likely to alter the metabolism of other drugs. In contrast to data with desipramine, data with amitriptyline and its active metabolite nortriptyline suggest no significant interaction with citalopram.<sup>6</sup> Any impact of escitalopram or citalopram on the pharmacokinetics of desipramine or other TCAs is likely the result of inhibition of the CYP2D6-mediated metabolism of the TCA, as escitalopram and citalopram are considered weak inhibitors of CYP2D6.<br><br>In addition to the potential risks associated with increased TCA concentrations, both TCAs and escitalopram share some toxicities, including serious toxicities such as serotonin syndrome or proarrhythmic effects, leading to a potential interaction where the potential for these serious toxicities is increased with concurrent use. Many antidepressants, including escitalopram/citalopram and the TCAs, possess an ability to enhance serotonin activity. Excessive serotonergic stimulation can cause clinically unwanted effects, and both escitalopram/citalopram and several individual TCAs have been associated with such toxicity.<sup>7,8,9,10,11,12</sup> The toxic effects associated with this condition may affect autonomic, neuromuscular, and cognitive function, and are termed “serotonin toxicity” or “serotonin syndrome” under some circumstances.<sup>7,8</sup> Concomitant use of 2 or more of these agents may increase the risk of toxic effects due to central serotonergic overstimulation. <br><br>Additionally, both escitalopram/citalopram<sup>13,14,15,16,17,18,19,20,21</sup> and many TCAs<sup>22,23,24,25</sup> have been associated with some potential to cause ECG changes, including prolongation of the QT interval and/or torsades de pointes. Due to questions about the clinical significance of their cardiac effects and the magnitude of their effects at therapeutic concentrations, the TCAs are generally considered to have an indeterminate risk for prolonging the QT interval and causing proarrhythmic effects. In contrast, citalopram is generally classified as having a high risk for prolonging the QT interval and causing proarrhythmic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lexapro (escitalopram). St. Louis, MO: Forest Laboratories, Inc., 12/2012.</p>\n<p>2. Gram LF, Hansen MG, Sindrup SH, et al, “Citalopram: Interaction Studies with Levomepromazine, Imipramine, and Lithium,” <i>Ther Drug Monit</i>, 1993, 15(1):18-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8451775\">[PubMed 8451775]</a></p>\n<p>3. Gupta S, Masand PS, “Effect of Citalopram on Blood Desipramine Levels,” <i>Prim Care Companion J Clin Psychiatry</i>, 2000, 2(1):28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15014667\">[PubMed 15014667]</a></p>\n<p>4. Haffen E, Vandel P, Broly F, et al, “Citalopram: An Interaction Study with Clomipramine in a Patient Heterozygous for CYP2D6 Genotype,” <i>Pharmacopsychiatry</i>, 1999, 32(6):232-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10599932\">[PubMed 10599932]</a></p>\n<p>5. Musshoff F, Schmidt P, Madea B, “Fatality Caused by a Combined Trimipramine-Citalopram Intoxication,” <i>Forensic Sci Int</i>, 1999, 106(2):125-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10664899\">[PubMed 10664899]</a></p>\n<p>6. Baettig D, Bondolfi G, Montaldi S, et al, “Tricyclic Antidepressant Plasma Levels after Augmentation with Citalopram: A Case Study,” <i>Eur J Clin Pharmacol</i>, 1993, 44(4):403-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8513856\">[PubMed 8513856]</a></p>\n<p>7. Dunkley EJ, Isbister GK, Sibbritt D, et al, “The Hunter Serotonin Toxicity Criteria: Simple and Accurate Diagnostic Decision Rules for Serotonin Toxicity,” <i>QJM</i>, 2003, 96(9):635-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12925718\">[PubMed 12925718]</a></p>\n<p>8. Sternbach H, “The Serotonin Syndrome,” <i>Am J Psychiatry</i>, 1991, 148(6):705-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2035713\">[PubMed 2035713]</a></p>\n<p>9. Huska MT, Catalano G, Catalano MC, “Serotonin Syndrome Associated with the Use of Escitalopram,” <i>CNS Spectr</i>, 2007, 12(4):270-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17426664\">[PubMed 17426664]</a></p>\n<p>10. Turedi S, Eraydin I, Gunduz A, et al, “First Time, Low Dose Citalopram Use-Related Serotonin Syndrome,” <i>Neurotoxicology</i>, 2007, 28(6):1272-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18213744\">[PubMed 18213744]</a></p>\n<p>11. Tomaselli G, Modestin J, “Repetition of Serotonin Syndrome after Reexposure to SSRI--A Case Report,” <i>Pharmacopsychiatry</i>, 2004, 37(5):236-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15359377\">[PubMed 15359377]</a></p>\n<p>12. Voirol P, Hodel PF, Zullino D, et al, “Serotonin Syndrome after Small Doses of Citalopram or Sertraline,” <i>J Clin Psychopharmacol</i>, 2000, 20(6):713-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11106153\">[PubMed 11106153]</a></p>\n<p>13. Tseng PT, Lee Y, Lin YE, et al, “Low-Dose Escitalopram for 2 Days Associated with Corrected QT Interval Prolongation in a Middle-Aged Woman: A Case Report and Literature Review,” <i>Gen Hosp Psychiatry</i>, 2012, 34(2):210.e13-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22133983\">[PubMed 22133983]</a></p>\n<p>14. Castro VM, Clements CC, Murphy SN, et al, “QT Interval and Antidepressant Use: A Cross Sectional Study of Electronic Health Records,” <i>BMJ</i>, 2013, 346:f288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23360890\">[PubMed 23360890]</a></p>\n<p>15. Deshmukh A, Ulveling K, Alla V, et al, “Prolonged QTc Interval and Torsades de Pointes Induced by Citalopram,” <i>Tex Heart Inst J</i>, 2012, 39(1):68-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22412232\">[PubMed 22412232]</a></p>\n<p>16. Fayssoil A, Issi J, Guerbaa M, et al, “Torsade de Pointes Induced by Citalopram and Amiodarone,” <i>Ann Cardiol Angeiol (Paris)</i>, 2011, 60(3):165-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21295285\">[PubMed 21295285]</a></p>\n<p>17. Jimmink A, Caminada K, Hunfeld NG, et al, “Clinical Toxicology of Citalopram after Acute Intoxication with the Sole Drug or in Combination with Other Drugs: Overview of 26 Cases,” <i>Ther Drug Monit</i>, 2008, 30(3):365-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18520609\">[PubMed 18520609]</a></p>\n<p>18. Astrom-Lilja C, Odeberg JM, Ekman E, et al, “Drug-Induced Torsades de Pointes: A Review of the Swedish Pharmacovigilance Database,” <i>Pharmacoepidemiol Drug Saf</i>, 2008, 17(6):587-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18449951\">[PubMed 18449951]</a></p>\n<p>19. Poluzzi E, Raschi E, Moretti U, et al, “Drug-Induced Torsades de Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS),” <i>Pharmacoepidemiol Drug Saf</i>, 2009, 18(6):512-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19358226\">[PubMed 19358226]</a></p>\n<p>20. Blaschke D, Parwani AS, Huemer M, et al, “Torsade de Pointes during Combined Treatment with Risperidone and Citalopram,” <i>Pharmacopsychiatry</i>, 2007, 40(6):294-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18030657\">[PubMed 18030657]</a></p>\n<p>21. Kanjanauthai S, Kanluen T, Chareonthaitawee P, “Citalopram Induced Torsade de Pointes, a Rare Life Threatening Side Effect,” <i>Int J Cardiol</i>, 2008, 131(1):e33-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17919753\">[PubMed 17919753]</a></p>\n<p>22. Okayasu H, Ozeki Y, Fujii K, et al, “Pharmacotherapeutic Determinants for QTc Interval Prolongation in Japanese Patients with Mood Disorder,” <i>Pharmacopsychiatry</i>, 2012, 45(7):279-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22592502\">[PubMed 22592502]</a></p>\n<p>23. van Noord C, Straus SM, Sturkenboom MC, et al, “Psychotropic Drugs Associated with Corrected QT Interval Prolongation,” <i>J Clin Psychopharmacol</i>, 2009, 29(1):9-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19142100\">[PubMed 19142100]</a></p>\n<p>24. Goodnick PJ, Jerry J, Parra F, “Psychotropic Drugs and the ECG: Focus on the QTc Interval,” <i>Expert Opin Pharmacother</i>, 2002, 3(5):479-98. (review) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11996627\">[PubMed 11996627]</a></p>\n<p>25. Rodriguez de la Torre B, Dreher J, Malevany I, et al, “Serum Levels and Cardiovascular Effects of Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors in Depressed Patients,” <i>Ther Drug Monit</i>, 2001, 23(4):435-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11477329\">[PubMed 11477329]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7692":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Heparin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparin may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitoring serum potassium concentrations closely in patients receiving angiotensin-converting enzyme inhibitors in combination with heparin.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 10 patients treated with captopril or enalapril, the use of heparin for venous thromboembolism prophylaxis was associated with an increase in serum potassium concentration from an average of 4.5 mM at baseline to a maximum of 6.2 mM after 4-8 days of prophylaxis.<sup>1</sup> Serum potassium over 5.5 mM was documented in all patients. Patients in this study had several established or potential risk factors for development of hyperkalemia; all had chronic renal insufficiency, 8 had acute declines in renal function; 6 were older than 70 years old, 3 had insulin dependent diabetes, and 1 was also taking indomethacin. <br><br>Canadian product monographs for angiotensin-converting enzyme inhibitors warn that their combination with other drugs associated with hyperkalemia could elevate the risk of hyperkalemia, specifically listing heparin and low molecular weight heparins as potential contributors to such effects.<sup>2,3,4,5</sup> Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, possibly related to suppression of aldosterone production, likely related to suppression of adrenal aldosterone secretion. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Durand D, Ader JL, Rey JP, et al, “Inducing Hyperkalemia by Converting Enzyme Inhibitors and Heparin,” <i>Kidney Int Suppl</i>, 1988, 25:S196-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3184611\">[PubMed 3184611]</a></p>\n<p>2. Product monograph. Lotensin (benazepril). Dorval, QC: Novartis Pharmaceuticals Canada Inc., March 2013.</p>\n<p>3. Product monograph. Captopril. Montreal, QC: Sorres Pharma Inc., April 2010.</p>\n<p>4. Product monograph. Ram-Fosinopril (fosinopril). Mississauga, ON: Ranbaxy Pharmaceuticals Canada Inc., April 2009.</p>\n<p>5. Product monograph. Vasotec (enalapril). Kirkland, QC: Merck Canada Inc., June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7693":"<p><b>Title</b> Angiotensin II Receptor Blockers / Heparin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparin may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitoring serum potassium concentrations closely in patients receiving angiotensin II antagonists in combination with heparin.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n</div> \n<p><b>Discussion</b> The U.S. prescribing information for at least one angiotensin II receptor blocker (ARB) cautions that concurrent use with drugs that increase potassium concentrations may increase the risk for hyperkalemia.<sup>1</sup> Similarly, the U.K. summary of product characteristics for heparin states that its use in combination with ARBs may elevate the risk of hyperkalemia.<sup>2</sup> Heparin and low molecular weight heparins have been associated with increases in serum potassium,<sup>3</sup> likely related to suppression of adrenal aldosterone secretion, although the magnitude of any interaction between these agents and ARBs has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Diovan (valsartan) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; July 2015.</p>\n<p>2. Heparin [summary of product characteristics]. Buckinghamshire, UK: Leo Laboratories Limited; June 2010.</p>\n<p>3. Bengalorkar GM, Sarala N, Venkatrathnamma PN, Kumar TN. Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels. <i>J Pharmacol Pharmacother</i>. 2011;2(4):266-269. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22025855\">[PubMed 22025855]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7694":"<p><b>Title</b> Potassium-Sparing Diuretics / Heparin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparin may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitoring serum potassium concentrations closely in patients receiving potassium-sparing diuretics in combination with heparin. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.</p>\n<div>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone, Triamterene</p>\n</div> \n<p><b>Discussion</b> Spironolactone U.S. prescribing information warns that its combination with other drugs associated with hyperkalemia could result in severe hyperkalemia.<sup>1</sup> Heparin and low molecular weight heparins are specifically listed as potential contributors to such effects, and have been widely reported as potential causes of hyperkalemia (likely related to suppression of adrenal aldosterone secretion), although the magnitude of any interaction between these agents and spironolactone or other potassium sparing diuretics has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aldactone (spironolactone). New York, NY: Pfizer Inc, June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7695":"<p><b>Title</b> Eplerenone / Heparin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparin may enhance the hyperkalemic effect of Eplerenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitoring serum potassium concentrations closely in patients receiving eplerenone in combination with heparin.</p> \n<p><b>Discussion</b> Eplerenone is an aldosterone antagonist, with one of its actions being to decrease sodium and water retention in the kidney, which results in greater potassium retention.<sup>1</sup> Its combination with potassium supplements or other medications that can increase serum potassium may increase the risk of hyperkalemia. Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, likely related to suppression of adrenal aldosterone secretion, although the magnitude of any interaction between these agents and eplerenone has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Inspra (eplerenone). New York, NY: Pfizer Inc., February 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7696":"<p><b>Title</b> Aliskiren / Heparin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparin may enhance the hyperkalemic effect of Aliskiren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitoring serum potassium concentrations closely in patients receiving aliskiren in combination with heparin.</p> \n<p><b>Discussion</b> The U.K. summary of product characteristics for aliskiren states that its use in combination with other drugs that may increase serum potassium may elevate the risk of hyperkalemia, specifically listing heparin as a potential contributor to such effects.<sup>1</sup> Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, likely related to suppression of adrenal aldosterone secretion, although the magnitude of any interaction between these agents and aliskiren has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Rasilez (aliskiren). Surrey, UK: Novartis Pharmaceuticals UK Ltd, February 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7697":"<p><b>Title</b> Canagliflozin / Heparin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparin may enhance the hyperkalemic effect of Canagliflozin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitoring serum potassium concentrations closely in patients receiving canagliflozin in combination with heparin.</p> \n<p><b>Discussion</b> Canagliflozin U.S. prescribing information states that its coadministration with medications that reduce potassium excretion (e.g., potassium sparing diuretics and medications that inhibit the renin-angiotensin-aldosterone system) may predispose patients to development of hyperkalemia.<sup>1</sup> Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, likely related to suppression of adrenal aldosterone secretion, although the magnitude of any interaction between these agents and canagliflozin has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invokana (canagliflozin). Titusville, NJ: Janssen Pharmaceuticals, Inc., March 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7698":"<p><b>Title</b> Potassium Salts / Heparin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparin may enhance the hyperkalemic effect of Potassium Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitoring serum potassium concentrations closely in patients receiving potassium salts in combination with heparin.</p>\n<div>\n <p><b>Potassium Salts Interacting Members</b> Potassium Acetate, Potassium Chloride, Potassium Citrate, Potassium Gluconate, Potassium Iodate, Potassium Iodide, Potassium Phosphate</p>\n</div> \n<p><b>Discussion</b> Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, likely related to suppression of adrenal aldosterone secretion.<sup>1</sup> Use of these agents in combination with potassium supplements or other medications that can increase serum potassium may therefore increase the risk of hyperkalemia. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Heparin. Buckinghamshire, UK: Leo Laboratories Limited, June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7699":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Heparins (Low Molecular Weight)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations closely in patients receiving angiotensin-converting enzyme inhibitors in combination with low molecular weight heparins.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Heparins (Low Molecular Weight) Interacting Members</b> Bemiparin, Dalteparin, Enoxaparin, Nadroparin, Tinzaparin</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 10 patients treated with captopril or enalapril, the use of heparin for venous thromboembolism prophylaxis was associated with an increase in serum potassium concentration from an average of 4.5 mM at baseline to a maximum of 6.2 mM after 4-8 days of prophylaxis.<sup>1</sup> Serum potassium over 5.5 mM was documented in all patients. Patients in this study had several established or potential risk factors for development of hyperkalemia; all had chronic renal insufficiency, 8 had acute declines in renal function; 6 were older than 70 years old, 3 had insulin dependent diabetes, and 1 was also taking indomethacin. <br><br>Canadian product monographs for angiotensin-converting enzyme inhibitors warn that their combination with other drugs associated with hyperkalemia could elevate the risk of hyperkalemia, specifically listing heparin and low molecular weight heparins as potential contributors to such effects.<sup>2,3,4,5</sup> Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, possibly related to suppression of aldosterone production, likely related to suppression of adrenal aldosterone secretion. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Durand D, Ader JL, Rey JP, et al, “Inducing Hyperkalemia by Converting Enzyme Inhibitors and Heparin,” <i>Kidney Int Suppl</i>, 1988, 25:S196-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3184611\">[PubMed 3184611]</a></p>\n<p>2. Product monograph. Lotensin (benazepril). Dorval, QC: Novartis Pharmaceuticals Canada Inc., March 2013.</p>\n<p>3. Product monograph. Captopril. Montreal, QC: Sorres Pharma Inc., April 2010.</p>\n<p>4. Product monograph. Ram-Fosinopril (fosinopril). Mississauga, ON: Ranbaxy Pharmaceuticals Canada Inc., April 2009.</p>\n<p>5. Product monograph. Vasotec (enalapril). Kirkland, QC: Merck Canada Inc., June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}